Mixing and delivery systems and needle hubs for same

The syringe assembly with a needle hub and non-invasive valve system addresses the challenges of high costs and complexity in dual chamber syringes by enabling efficient mixing and delivery of pharmaceutical components, enhancing manufacturing efficiency and user-friendliness.

WO2026241664A1PCT designated stage Publication Date: 2026-11-19SOLUTION MEDICAL LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028418
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Dual chamber syringes for medicaments are expensive to manufacture and lack simplicity for end-users, and producing lyophilized powdered medicaments in situ is difficult, hindering rapid and large-scale manufacturing.

Method used

A syringe assembly with a housing and a needle hub that allows for the mixing and delivery of two pharmaceutical components, featuring transfer needles that pierce seals to combine the components within the syringe, and a non-invasive valve system to maintain sterility and reduce manufacturing costs.

Benefits of technology

The solution provides a cost-effective and user-friendly syringe system for mixing and delivering medicaments, ensuring sterility and facilitating rapid, large-scale manufacturing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028418_19112026_PF_FP_ABST
    Figure US2026028418_19112026_PF_FP_ABST
Patent Text Reader

Abstract

A needle hub and reconstitution device, and a system comprising the same, is described herein. The needle hub features a needle connector facing away from the housing and at least two transfer needles extending towards the housing. The transfer needles are designed to pierce at least two seals of at least two pharmaceutical component-mixing delivery assemblies when the needle hub is in the second position. The system described herein is intended for reconstituting and delivering mixed pharmaceutical components.
Need to check novelty before this filing date? Find Prior Art

Description

260493.000069MIXING AND DELIVERY SYSTEMS AND NEEDLE HUBS FOR SAMECROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 807,376 filed May 16, 2025 (Attorney Docket No.: 260493.000041), which is incorporated by reference as if set forth in full herein.FIELD OF THE INVENTION

[0002] The present disclosure relates to syringes and corresponding needle hubs suitable for respectively mixing and / or reconstituting two pairs of therapeutic components and delivering same.

[0003] More particularly, the disclosure relates to a syringe suitable for mixing two sets of two component therapeutic, such as a solid or liquid medicament and a liquid diluent. The present disclosure also relates to novel detachably attachable needle hubs to deliver the mixed medicaments from the syringe.BACKGROUND

[0004] Many medicaments are unsuitable for the long-term storage as a liquid solution because they may be unstable when mixed into a solution and thus have a shorter shelflife than other forms. Such medicaments may be reconstituted with a diluent or carrier, usually a liquid, prior to administration. Thus, liquid or solid medicaments may be stored in a sealed vial prior to reconstitution. Increasingly, prefilled syringes capable of separate storage of at least two different components are being used. Such syringes usually comprise a medicinal component stored in a first chamber and a dissolving or dispersing component in a second chamber. The components are kept apart until use.

[0005] Dual chamber syringes have been developed which can suitably be used with powdered or liquid medicaments and a suitable liquid diluent. Such dual chambers may be used for the administration of “biopharmaceuticals,” such as recombinant proteins; and the like. One disadvantage of dual chamber syringes on the market is that they are expensive to manufacture and can lack simplicity for the end-user. Producing a260493.000069lyophilized powdered medicament in situ in the syringe can also be difficult and does not lend itself to rapid and large scale manufacturing techniques. These and other issues exist.SUMMARY

[0006] The present disclosure provides solutions to the aforementioned issues. The disclosure provides example syringes and corresponding needle hubs suitable for separately mixing two pairs of components and delivering same. More particularly, the solutions described herein relate to needle hubs to deliver the mixed medicament from the syringe.

[0007] An aspect of the present disclosure provides a syringe assembly. The syringe assembly includes a housing and a needle hub. The needle hub is engageable with the housing and movable from a first position with respect to the housing to a second position with respect to the housing. The needle hub includes a needle connector and first and second transfer needles. The needle connector is positioned such that it faces away from the housing when the needle hub is engaged with the housing. The first transfer needle is oriented such that the first transfer needle extends away from the needle connector, with the first transfer needle being configured to pierce a seal of a first pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position. The second transfer needle is positioned such that the second transfer needle extends away from the needle connector, the second transfer needle configured to pierce a seal of a second pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position.

[0008] Another aspect of the present disclosure provides a method. The method includes connecting a needle hub to a distal end of a housing. The method includes inserting a first pharmaceutical component-mixing delivery assembly into a proximal end of the housing. The method includes inserting a second pharmaceutical componentmixing delivery assembly into the proximal end of the housing. The method includes securing the first and second pharmaceutical component-mixing deliveries assembly within the housing. The method includes moving the needle hub from a first position with respect to the housing to a second position with respect to the housing, such that first and second transfer needles of the needle hub moves proximally toward the first and second260493.000069pharmaceutical component-mixing delivery assemblies. The method includes piercing, in response to proximal movement of the first and second transfer needles, a first seal of the first pharmaceutical component-mixing delivery assembly with the first transfer needle and a second seal of the second pharmaceutical component-mixing delivery assembly with the second transfer needle.

[0009] An aspect of the present disclosure provides a system. The system includes a first pharmaceutical component-mixing delivery assembly, a second pharmaceutical component-mixing delivery assembly, and a syringe assembly. The first pharmaceutical component-mixing delivery assembly contains a first pharmaceutical component. The second pharmaceutical component-mixing delivery assembly contains a second pharmaceutical component. The syringe assembly includes a housing, a fluidic path, and an outlet. The first and second pharmaceutical component-mixing delivery assemblies are disposed within the housing. The first pharmaceutical component and the second pharmaceutical component exit the syringe assembly through the outlet. The outlet is connected to the fluidic path such that the first component and the second component converge prior to exiting the syringe assembly.BRIEF DESCRIPTION OF THE DRAWINGS

[0010] FIGs. 1 (a) to (d) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising a ball valve component.

[0011] FIGs. 2 (a) to (d) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising a ball valve component provided with ball displacement means.

[0012] FIGs. 3 (a) to (e) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising a T-valve component.

[0013] FIGs. 4 (a) to (e) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising an “annular valve” component.

[0014] FIGs. 5 (a) to (d) are cross-sectional views of a sealed pharmaceutical component-mixing delivery assembly comprising a partially threaded plunger and “needle valve” component.260493.000069

[0015] FIGs. 6 (a) to (d) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising a spigot plug component.

[0016] FIGs. 7 (a) and 7 (b) are cutaway perspective views of a pharmaceutical component-mixing delivery assembly comprising a spigot plug component of FIG. 6; and FIG. 7 (c) is a perspective view of the delivery assembly of FIG. 6.

[0017] FIGs. 8 (a) to (d) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising a hollow plug component.

[0018] FIGs. 9 (a) and 9 (b) are cutaway perspective views of a pharmaceutical component-mixing delivery assembly comprising a hollow plug component of FIG. 8; FIG. 9 (c) is a perspective view of the delivery assembly of FIG. 8.

[0019] FIGs. 10 (a) and (b) are cross-sectional views of a pharmaceutical componentmixing delivery assembly comprising a ribbed non-invasive valve component.

[0020] FIGs. 11 (a) and 11 (b) are cutaway perspective views of a pharmaceutical component-mixing delivery assembly comprising ribbed non-invasive valve component of FIG. 10.

[0021] FIG. 11 (c) is a perspective view of the delivery assembly of FIG. 10.

[0022] FIG. 12 is a cutaway perspective view of a non-invasive valve component of a pharmaceutical component-mixing delivery assembly.

[0023] FIG. 13 A shows a disassembled needle hub and a transfer needle, and FIG. 13B shows the needle hub of FIG. 13A assembled.

[0024] FIG. 14A shows an example housing.

[0025] FIG. 14B shows a housing with a needle hub connected thereto, and FIG. 14C is a cross-sectional view of the housing with needle hub shown in FIG. 14B.

[0026] FIG. 15A is a detailed view of a needle hub assembled to a housing prior to attaching a delivery needle, and FIG. 15B is a detailed view of the assembly of FIG. 15A after attaching the delivery needle.

[0027] FIG. 16A shows the step of assembling a pharmaceutical component-mixing delivery assembly with a housing comprising a needle hub, and FIG. 16B shows the assembly, housing, and needle hub assembled.

[0028] FIG. 17A shows the step of adding an end cap to the assembly shown in FIG.16B, and FIG. 17B shows the assembly assembled with the end cap.260493.000069

[0029] FIG. 18A shows the step of adding a plunger to the assembly shown in FIG.17B, and FIG. 18B shows the assembly assembled with the plunger.

[0030] FIG. 19 shows a fully assembled device with a needle hub after delivering a reconstituted medicaments using the device.

[0031] FIG. 20 is a flowchart for an example method for using a syringe assembly.

[0032] FIGs. 21A-21F show steps to fill a pharmaceutical component-mixing delivery assembly. FIG. 21 A shows the step of adding a spigot plug component to a first cartridge. FIG. 2 IB shows the step of adding a first pharmaceutical component to the first cartridge. FIG. 21 C shows the step of adding a plunger stopper to the first cartridge. FIG. 2 ID shows the step of adding a second pharmaceutical component into a sealed second cartridge. FIG. 21E shows the step of adding a piston component to the first cartridge. FIG. 21F shows the step of adding the first cartridge to the second cartridge.

[0033] FIG. 22 is a flowchart for an example method for filling a pharmaceutical component-mixing delivery assembly via a rear-fill method.

[0034] FIGs. 23A-23G show steps to fill a pharmaceutical component-mixing delivery assembly. FIG. 23 A shows the step of adding a spigot plug component to a first cartridge. FIG. 23B shows the step of adding a first pharmaceutical component to the first cartridge. FIG. 23 C shows the step of adding a plunger stopper to the first cartridge. FIG. 23D shows the step of adding a piston component to the first cartridge. FIG. 23E shows the step of adding the first cartridge of FIG. 23D to an empty and distally-open second cartridge. FIG. 23F shows the step of inverting the assembly shown in FIG. 23E and adding a second pharmaceutical component into the distal end of the second cartridge. FIG. 23G sealing the distal end of the second cartridge with a cartridge cap.

[0035] FIG. 24 is a flowchart for an example method for filling a pharmaceutical component-mixing delivery assembly via a tip-fill method.

[0036] FIGs. 25A-25C are cross-sectional views showing use of a syringe assembly, according to aspects of the present disclosure.

[0037] FIG. 26 is a perspective view of a syringe assembly, with a needle hub thereof partially cut away, according to aspects of the present disclosure.

[0038] FIGs. 27A-27D are elevation views showing use of the syringe assembly of FIG.26, according to aspects of the present disclosure.260493.000069

[0039] FIG. 28A is a distal perspective view of a spigot plug component, according to aspects of the present disclosure.

[0040] FIG. 28B is a proximal perspective view of the spigot plug component of FIG.28A, according to aspects of the present disclosure.

[0041] FIG. 28C is a cross-sectional view of the spigot plug component of FIG. 28A, according to aspects of the present disclosure.

[0042] FIG. 28D is an elevation view of the spigot plug component of FIG. 28A, according to aspects of the present disclosure.

[0043] FIG. 29A is a distal perspective view of a spigot plug component, according to aspects of the present disclosure.

[0044] FIG. 29B is a proximal perspective view of the spigot plug component of FIG.29A, according to aspects of the present disclosure.

[0045] FIG. 29C is a cross-sectional view of the spigot plug component of FIG. 29A, according to aspects of the present disclosure.

[0046] FIG. 29D is an elevation view of the spigot plug component of FIG. 29A, according to aspects of the present disclosure.

[0047] FIG. 30A is a proximal perspective view of a plunger stopper, according to aspects of the present disclosure.

[0048] FIG. 30B is a distal perspective view of the plunger stopper of FIG. 30A, according to aspects of the present disclosure.

[0049] FIG. 30C is an elevation view of the plunger stopper of FIG. 30A, according to aspects of the present disclosure.

[0050] FIG. 30D is a cross-sectional view of the plunger stopper of FIG. 30A, according to aspects of the present disclosure.

[0051] FIG. 31 is a flowchart for an example method for using a syringe assembly.DETAILED DESCRIPTION

[0052] The present disclosure can be understood more readily by reference to the following detailed description of exemplary embodiments and the examples included herein. Before the exemplary embodiments of the devices and methods according to the present disclosure are disclosed and described, it is to be understood that embodiments260493.000069are not limited to those described within this disclosure. Numerous modifications and variations therein will be apparent to those skilled in the art and remain within the scope of the disclosure. It is also to be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting. Some embodiments of the disclosed technology will be described more fully hereinafter with reference to the accompanying drawings. This disclosed technology may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth therein.

[0053] In the following description, numerous specific details are set forth. But it is to be understood that embodiments of the disclosed technology may be practiced without these specific details. In other instances, well-known methods, structures, and techniques have not been shown in detail in order not to obscure an understanding of this description. References to “one embodiment,” “an embodiment,” “example embodiment,” “some embodiments,” “certain embodiments,” “various embodiments,” etc., indicate that the embodiment(s) of the disclosed technology so described may include a particular feature, structure, or characteristic, but not every embodiment necessarily includes the particular feature, structure, or characteristic. Further, repeated use of the phrase “in one embodiment” does not necessarily refer to the same embodiment, although it may.

[0054] Unless otherwise noted, the terms used herein are to be understood according to conventional usage by those of ordinary skill in the relevant art. In addition to any definitions of terms provided below, it is to be understood that as used in the specification and in the claims, “a” or “an” can mean one or more, depending upon the context in which it is used. Throughout the specification and the claims, the following terms take at least the meanings explicitly associated herein, unless the context clearly dictates otherwise. The term “or” is intended to mean an inclusive “or.” Further, the terms “a,” “an,” and “the” are intended to mean one or more unless specified otherwise or clear from the context to be directed to a singular form.

[0055] Unless otherwise specified, the use of the ordinal adjectives “first,” “second,” “third,” etc., to describe a common object, merely indicate that different instances of like objects are being referred to, and are not intended to imply that the objects so described260493.000069must be in a given sequence, either temporally, spatially, in ranking, or in any other manner.

[0056] Also, in describing the exemplary embodiments, terminology will be resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents that operate in a similar manner to accomplish a similar purpose.

[0057] To facilitate an understanding of the principles and features of the embodiments of the present disclosure, exemplary embodiments are explained hereinafter with reference to their implementation in an illustrative embodiment. Such illustrative embodiments are not, however, intended to be limiting.

[0058] The materials described hereinafter as making up the various elements of the embodiments of the present disclosure are intended to be illustrative and not restrictive. Many suitable materials that would perform the same or a similar function as the materials described herein are intended to be embraced within the scope of the example embodiments. Such other materials not described herein can include, but are not limited to, materials that are developed after the time of the development of the disclosed technology, for example.

[0059] Embodiments of the disclosed technology include detachably attachable needle hubs that can be used to deliver mixed medicament from a dual chambered reconstitution device. But examples of the disclosed technology are not so limited. The disclosed needle hub devices and techniques may be effective in delivering medicament from other fluid delivery devices, including for example single-chamber fluid delivery devices, or even fluid delivery devices with more than two separate chambers / compartments. Also, the devices described herein can be used to deliver any number of medicaments. Some examples described herein can include reconstituting a pharmaceutical component (e.g., the later mentioned second pharmaceutical component (11) within second cartridge (3)) using another pharmaceutical component (usually a liquid, see for example the later mentioned first pharmaceutical component (7) within first cartridge (2)). It will be understood that the second pharmaceutical component (11) can be a solid component (e.g. , a powder) that is created, for example and not limitation, via lyophilization or spraydrying.260493.000069

[0060] According to one aspect of the present disclosure there is described a pharmaceutical component-mixing delivery assembly comprising: a first cartridge and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with plunger and containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; and wherein the first and second cartridges are separated by a non-invasive valve component.

[0061] In a particular embodiment the non-invasive valve component, e.g., comprising a piston, can include a terminal rib, that is, a circumferential rib located at the end of the non-invasive valve component nearest to the open end of the second cartridge. The inclusion of a terminal rib is advantageous in that, inter alia, it allows the sterility of the delivery assembly to be maintained when the device is primed before injection.

[0062] Furthermore, the non-invasive valve component, e.g., a piston, may be generally elongated. The region of the second cartridge that contains the second pharmaceutical component can include an aseptic mixing chamber, whilst the inner wall of the second cartridge outside of the mixing chamber and beyond the terminal rib of the piston, will generally be non-aseptic. In use, as the plunger of the delivery assembly is depressed and the piston moves towards the inlet end of the second cartridge, the mixing chamber essentially expands longitudinally. Thus, the length of the piston is desirably chosen so that as the piston moves, the mixing chamber never comes into contact with the nonaseptic walls of the second cartridge and the sterility of the mixing chamber is maintained at all times. Therefore, the length of the piston will be dictated by how far back along the second cartridge it has to move, which will in turn be dictated by the volume required for the mixing chamber.

[0063] The non-invasive valve component can comprise a ball valve, a flow through stopper component or a T-shaped stopper component.

[0064] The pharmaceutical component-mixing delivery assembly can include a syringe assembly. Thus, the pharmaceutical component-mixing delivery assembly hereinbefore260493.000069described may include a needle, e.g., a hypodermic needle, attached to the outlet end of the second cartridge.

[0065] One of the first and second pharmaceutical components may comprise a solid therapeutically active component or agent, and the other is a liquid capable of solubilizing or forming a suspension with the solid therapeutically active component. In a particular aspect of the disclosure the first pharmaceutical component comprises a liquid and the second pharmaceutical component comprises a solid therapeutically active component. However, it will be understood by the person skilled in the art that the first and second pharmaceutical components may comprise liquid / liquid components, viscous / non-viscous components, etc.

[0066] The first and second pharmaceutical component of the present invention may include any and all active ingredients considered appropriate, normal, standard, and / or typical for treating a target disease, disorder, or condition, including drugs at any stage of the drug development process / pipeline, including but not limited to, active ingredients that are in preclinical development, drugs undergoing clinical trials / marketing approval, drugs approved for use, marketed drugs, and / or drugs in early, middle, or late stages of development, including repurposed and / or reformulated drugs. General mention is made of any and all hormone drugs, antibody therapeutics, autoinjector drugs, self-injection drugs and / or drugs involving reconstitution systems for delivery. Additional active ingredients include, but are not limited to, antibacterial (e g. beta-lactam antibiotics, penicillin, vancomycin, ciprofloxacin), antiviral (e g. acyclovir, oseltamivir) and antifungal (e.g. naftifine, nystatin) substances and immunomodulatory and immunosuppressive compounds such as cyclosporin, Methotrexate®, TNF antagonists (e.g. Humira®, Etanercept, infliximab), IL-1 inhibitors (e.g. Anakinra, Canakinumab, Rilonacept), phosphodiesterase inhibitors (e.g. Apremilast), Jak / STAT inhibitors (e.g. Tofacitinib, Baricitinib, GLPG0634), leflunomide, cyclophosphamide, rituximab, belimumab, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids (e.g. prednisone, prednisolone, methylprednisolone, hydrocortisone, betamethasone), cyclophosphamide, azathioprine, sulfasalazine, paracetamol and non-steroidal antiinflammatory substances (NSAIDS) (e.g., aspirin, ibuprofen, naproxen, etodolac, celecoxib, colchicine).260493.000069

[0067] In some embodiments, the first and / or second pharmaceutical component of the present invention may include, but are not limited to, hydrocortisone, a hydrocortisone prodrug, or a pharmaceutically acceptable salt of hydrocortisone. In some embodiments, the hydrocortisone prodrug is a hydrocortisone ester. In some embodiments, the hydrocortisone prodrug or pharmaceutically acceptable salt thereof of hydrocortisone is selected from hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone hydrogen succinate, hydrocortisone butyrate, and hydrocortisone acetate. In some embodiments, the hydrocortisone prodrug or pharmaceutically acceptable salt thereof is hydrocortisone sodium phosphate.

[0068] In addition to the active ingredients mentioned above, the first and second pharmaceutical component of the present invention may also include, but are not limited to, the following active ingredients: Vitamin D analogs (e.g., calcipotriol, tacalcitol or calcitriol), salicylic acid, urea, cyclosporine, methotrexate, efalizumab for treatment of dermatological disorders; methotrexate and biologies for B-cell and T-cell therapy (e.g. rituximab, abatacept) for rheumatoid disorders, for example rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis; substances for treatment of pulmonary disorders, for example beta-2-sympathomimetics (e.g. salbutamol), anticholinergics (e.g. glycopyrronium), methylxanthines (e.g. theophylline), leukotriene receptor antagonists (e.g. montelukast), PDE-4 (phosphodiesterase type 4) inhibitors (e.g. roflumilast), methotrexate, IgE antibodies, azathioprine and cyclophosphamide, cortisol-containing preparations; lipid-lowering drugs, for example, fibrates (e.g. bezafibrate, etofibrate, fenofibrate, gemfibrozil), nicotinic acid derivatives (e.g. nicotinic acid / laropiprant), ezetimibe, statins (e.g. simvastatin, fluvastatin), anion exchangers (e.g. colestyramine, colestipol, colesevelam); active ingredients for treatment of cardiovascular disorders such as beta-blockers (e.g. metoprolol), ACE inhibitors (e.g. benazepril), angiotensin receptor blockers (e.g. losartan, valsartan), diuretics (e.g. hydrochlorothiazide), calcium-channel blockers (e.g. nifedipine), statins (e.g. simvastatin, fluvastatin); neurotrophic substances, such as, acetylcholinesterase inhibitors (e.g. donepezil), MAO (monoamine oxidase) inhibitors (e.g. selegiline), interferons and anticonvulsants (e.g. gabapentin); anti-diabetic drugs, for example metformin, glinides (e.g. repaglinide), DPP-4 (dipeptidyl peptidase-4) inhibitors (e.g. linagliptin, saxagliptin, sitagliptin, SGLT2 (sodium / glucose260493.000069cotransporter 2) inhibitors, gliflozin (e.g. dapagliflozin, empagliflozin), incretin mimetics (hormone glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) analogues / agonists (e.g. exenatide, liraglutide, lixisenatide), a-glucosidase inhibitors (e.g. acarbose, miglitol, voglibose) and sulfonylureas (e.g. glibenclamide, tolbutamide), insulin sensitizers (e.g. pioglitazone) and insulin therapy (e.g. NPH insulin, insulin lispro), substances for treatment of hypoglycemia, for treatment of diabetes and metabolic syndrome; beta-interferon (IFN-beta) (e.g. IFN beta- lb, IFN beta- la, Avonex® and Betaferon®), glatiramer acetate, immunoglobulins, natalizumab, fmgolimod and immunosuppressants such as mitoxantrone, azathioprine and cyclophosphamide for treatment of multiple sclerosis; and active ingredients for Alzheimer's therapy, for example, acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine, tacrine), NMDA (N-methyl-D-aspartate) receptor antagonists (e.g. memantine); L-DOPA / carbidopa (1,3,4-dihydroxyphenylalanine), COMT (catechol-O-methyltransferase) inhibitors (e.g. entacapone), dopamine agonists (e.g. ropinirole, pramipexole, bromocriptine), MAO-B (monoamine oxidase-B) inhibitors (e.g. selegiline), anticholinergics (e.g. trihexyphenidyl) and NMDA antagonists (e.g. amantadine) for treatment of Parkinson's Disease.

[0069] The use of a non-invasive valve as hereinbefore described is advantageous in that, inter alia, conventional syringe bodies and / or plungers may be utilized, significantly reducing the expense of the syringe assembly as a whole. It also avoids, for example, the need for an elastomeric septum.

[0070] In one aspect of the disclosure the non-invasive valve component may comprise a ball valve. Such a ball valve component may comprise one or more balls located within the outlet of the first cartridge, such that the ball(s) acts to seal the first cartridge. The ball valve component includes a substantially hollow apertured piston suitable for receiving the ball from the first cartridge.

[0071] More specifically, the ball valve component may comprise a substantially hollow apertured piston with a first end adjacent the outlet end of the first cartridge and a second end adjacent the inlet end of the second cartridge. The hollow apertured piston will comprise side walls which generally form a seal against the inner walls of the second cartridge.260493.000069

[0072] The first end of the piston may comprise means for locating the outlet end of the first cartridge. For example, such means may comprise a substantially circumferential ridge. The second end of the piston may comprise one or more apertures which, when in use, are dimensioned to allow fluid to flow.

[0073] A single ball or a plurality, e.g., two or three balls, may be located within the outlet of the first cartridge, such that the ball(s) acts to seal the first cartridge. In use, when the plunger is depressed within the first cartridge the fluid pressure will force the ball valve to open allowing fluid to flow from the first cartridge to the second cartridge enabling mixing to occur.

[0074] In another aspect of the disclosure the non-invasive valve component may comprise a ball valve as hereinbefore described. However, the second end of the piston may comprise a separate plug component which can include one or more apertures which, when in use, are dimensioned to allow fluid to flow. In addition, the plug component may be provided with means for displacing the ball from the outlet of the first cartridge allowing fluid to flow from the first cartridge to the second cartridge enabling mixing to occur. Thus, in accordance with this aspect of the disclosure there is described a pharmaceutical component-mixing delivery assembly as hereinbefore described wherein the ball valve component includes a plug component which can include one or more apertures and which can include a means for displacing the ball from the outlet of the first cartridge. One example of such displacement means is a plug provided with a protruding spigot.

[0075] In another aspect of the disclosure the non-invasive valve component may comprise a flow through stopper component. The flow through stopper component may comprise a stopper which can include a conduit means. Said conduit means may comprise an internal conduit within the stopper or alternatively, may comprise an external conduit, that is, a conduit between the walls of the piston and the stopper.

[0076] One example of a flow through stopper component with an internal conduit is a T-valve. Such a T-valve component may comprise a substantially hollow apertured piston with a first end adjacent the outlet end of the first cartridge and a second end adjacent the inlet end of the second cartridge. The hollow apertured piston will comprise side walls260493.000069which generally form a seal against the inner walls of the second cartridge as hereinbefore described.

[0077] The first end of the piston may comprise means for locating the outlet end of the first cartridge. For example, such means may comprise a substantially circumferential ridge. The piston also houses a stopper which has a flow through capability and which seals the outlet end of the first cartridge. Said stopper may comprise an internal conduit which is substantially coaxial with the longitudinal axis of the first cartridge, but which can include one or more branches which seal against the side walls of the piston.

[0078] In use, when the plunger is depressed within the first cartridge the fluid pressure will displace the flow through stopper such that the one or more branches of the conduit are no longer sealed against the side walls of the piston allowing fluid to flow from the first cartridge to the second cartridge enabling mixing to occur. Optionally, a second stopper may be provided adjacent the inlet of the second cartridge. The second stopper may also be provided with one or more branched conduits, which act in a substantially similar manner to the first.

[0079] In any of the embodiments described herein the side walls of the non-invasive valve component may be provided with one or more external ribs to improve the seal formed between the non-invasive valve component and the second cartridge. Thus, for example, when the non-invasive valve component comprises a piston, the piston may be ribbed, i.e., can include one or more external ribs, to improve the seal formed between the piston and the inner walls of the second cartridge. Preferably the piston can include one or more circumferential ribs. It is especially preferred for the piston to be provided with a plurality of circumferential ribs, e.g., 2, 3 or 4 ribs.

[0080] An alternative example of a flow through stopper component with an external conduit is an “annular valve”. Although an “annular valve” possesses a similar functionality to the aforementioned T-valve, the “annular valve” stopper itself does not comprise an internal conduit.

[0081] Adj acent the first cartridge the internal walls of the piston are configured to form a snug fit with the stopper. In this first position, the stopper seals the first cartridge. The piston also provides a second position wherein the stopper forms a loose fit, such a260493.000069conduit external to the stopper is formed between the stopper and the piston, such that fluid may pass through the conduit, between the walls of the piston and the stopper.

[0082] Thus, according to this aspect of the disclosure there is described a pharmaceutical component-mixing delivery assembly as hereinbefore described wherein the “annular valve” comprises a piston configured to form a snug fit with a stopper which seals the first cartridge; and wherein the piston provides a second position wherein the stopper forms a loose fit, such that fluid may pass between the walls of the piston and the stopper.

[0083] The use of a T-valve is advantageous, inter alia, in that:• It provides guidance for the piston in the hollow stopper (the plug cannot tilt) • Aids assembly — physical stop• Prevents the piston being accidently drawn back into the syringe• Ribs provide enhanced sealing in the neck of the of the cartridge• The larger diameter part is held by the hollow stopper which provides additional retention of the piston

[0084] According to a further aspect of the present disclosure there is described a method of operating a pharmaceutical component-mixing delivery assembly holding first and second pharmaceutical components; said delivery assembly comprising: a first cartridge and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with plunger and containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; and wherein the first and second cartridges are separated by a non-invasive valve component; said method comprising pressing the plunger axially into the first cartridge to an intermediate position thus pressurizing the first cartridge and opening the non-invasive valve component, causing the first pharmaceutical component to flow through the valve and into the second cartridge to mix with the second pharmaceutical component.260493.000069

[0085] According to a yet further aspect of the present disclosure there is described a method of administering a therapeutically active component to a patient which comprises operating a pharmaceutical component-mixing delivery assembly holding first and second pharmaceutical components; said delivery assembly comprising: a first cartridge and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with plunger and containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; and wherein the first and second cartridges are separated by a non-invasive valve component; said method comprising the steps of (i) pressing the plunger axially into the first cartridge to an intermediate position thus pressurizing the first cartridge and opening the a non-invasive valve component, causing the first pharmaceutical component to flow through the valve and into the second cartridge to mix with the second pharmaceutical component; (ii) after the first and second pharmaceutical components have mixed, administering the mixed pharmaceutical components to a patient.

[0086] According to a particular aspect of the method of the disclosure the non-invasive valve component can include a terminal rib to improve the seal formed between the non-invasive valve component and the second cartridge.

[0087] The pharmaceutical component-mixing delivery assembly can include a syringe assembly. Thus, the method of administering a therapeutically active component to a patient can include an additional step of attaching a needle, e.g., a hypodermic needle, to the outlet end of the second cartridge, followed by administering the mixed pharmaceutical components to a patient.

[0088] In the aforementioned methods preferably one of the first and second pharmaceutical components comprises a solid therapeutically active component and the other is a liquid capable of solubilizing or forming a suspension with the solid therapeutically active component. In a particular aspect of the disclosure the first pharmaceutical component comprises a liquid and the second pharmaceutical component260493.000069comprises a solid therapeutically active component. Alternatively, the first and second pharmaceutical components may comprise liquid / liquid components, viscous / non-viscous components, etc.

[0089] In another embodiment of the present disclosure resistance or friction may be minimized for the user by providing a plunger with an external screw thread. In this particular embodiment the plunger is desirably threaded along a predetermined portion of its length. It is within the scope of the present disclosure for the plunger to be threaded along the whole of its length; however, it is preferred that the plunger is only partially threaded, i.e., threaded along only a portion of its length. Thus, the user may screw the plunger to bring the contents of the first and second cartridges into contact, since this is generally where the user experiences most resistance. However, the remainder of the shaft of the plunger may desirably be unthreaded so that a conventional push action may be used for administration of the medicament solution to a patient.

[0090] The use of a threaded, or partially threaded, plunger as hereinbefore described may also be advantageous in that it may be used to provide a sealed system, improving sterility of the delivery device. Thus, a frangible seal may be provided around the shaft of the plunger, for example, within the body of the first cartridge, such that twisting of the plunger by the user can cause the frangible seal to break.

[0091] The use of a threaded plunger may suitably be used with any of the aforementioned syringe embodiments hereinbefore described. However, it will be understood by the person skilled in the art that such a threaded plunger arrangement is novel per se and may therefore be suitably applied to a conventionally known valve component, such as a needle piercing an elastomeric septum. Desirably, the pharmaceutical component-mixing delivery assembly according to this aspect of the disclosure can include a sealed unit, e.g., an outer casing which house the first and second cartridges.

[0092] A particular advantage of the use of a threaded plunger is that a seal may be placed around the end of the first cartridge by, i.e., between the first cartridge and the outer casing.

[0093] Thus, according to this further aspect of the present disclosure there is described a pharmaceutical component-mixing delivery assembly comprising: an outer casing is260493.000069provided which houses a first and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with an at least partially threaded plunger the end of which protrudes from the outer casing, said first cartridge containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; wherein the first and second cartridges are separated by a valve component; and a frangible seal is provided between the outer casing and the first cartridge.

[0094] In use, when the at least partially threaded plunger is twisted the frangible seal is broken; then as the at least partially threaded plunger and the cartridge are pushed towards the second cartridge the first cartridge disengages from the seal. The use of a frangible seal enables the device to remain sterile during storage, whilst the disengagement of the frangible seal from the first cartridge reduces friction and lowers force required to complete the administration of the therapeutically active component.

[0095] According to this aspect of the disclosure the valve component may comprise a non-invasive valve as hereinbefore described or a conventionally known valve, such as a needle valve or a bypass valve.

[0096] In a further aspect of the disclosure there is described a method of administering a therapeutically active component to a patient which comprises operating a pharmaceutical component-mixing delivery assembly holding first and second pharmaceutical components; said delivery assembly comprising: an outer casing is provided which houses a first and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with an at least partially threaded plunger the end of which protrudes from the outer casing, said first cartridge containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; wherein the first and second260493.000069cartridges are separated by a valve component; and a frangible seal is provided between the outer casing and the first cartridge.

[0097] The method of operation according to this aspect of the disclosure can include first turning the at least partially threaded plunger causing the frangible seal to break and disengage from the first cartridge and subsequently pressing the plunger to administer the mixed pharmaceutical components to a patient.

[0098] The term “non-invasive valve” will be understood by the person skilled in the art. However, for the avoidance of doubt, the term should be construed so as not to include a component wherein, for example, a needle is utilized to pierce a septum and the like. Furthermore, the term “non-invasive valve component” should be construed as meaning that the valve is made up entirely of the component, i.e., it does not utilize the wall of the syringe or cartridge.

[0099] According to a yet further aspect of the disclosure there is described a kit suitable for mixing and delivery of pharmaceutical components, said kit comprising: a first cartridge and a second cartridge; the first and second cartridges being dimensioned so that when placed together they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with plunger and containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; and wherein when the first and second cartridges are placed together they are separated by a non-invasive valve component.

[0100] The present disclosure also describes a kit suitable for mixing and delivery of pharmaceutical components, said kit comprising: an outer casing which houses a first and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with an at least partially threaded plunger the end of which protrudes from the outer casing, said first cartridge containing a first pharmaceutical component; the second cartridge260493.000069comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; wherein the first and second cartridges are separated by a valve component; and a frangible seal is provided between the outer casing and the first cartridge.

[0101] The disclosure further describes the use of a pharmaceutical component-mixing delivery assembly comprising: a first cartridge and a second cartridge; the first and second cartridges being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge from a pre-mixed position to a post-mixed position; the first cartridge comprising a body provided with an outlet end, the first cartridge being fitted with plunger and containing a first pharmaceutical component; the second cartridge comprising a body provided with an inlet end and an outlet end, the second cartridge containing a second pharmaceutical component; and wherein the first and second cartridges are separated by a non-invasive valve component; for the mixing and delivery of a first and second pharmaceutical component. According to this aspect of the disclosure the non-invasive valve component can include a terminal rib to improve the seal formed between the non-invasive valve component and the second cartridge.

[0102] Reference will now be made to the figures, in which similar structures will be provided with similar reference designations. Referring to FIGs. 1 (a) to (d) a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3), the first cartridge (2) being dimensioned so that it is slidable within the second cartridge (3) from a pre-mixed position to a post-mixed position. The first cartridge (2) comprises a body (4) provided with an outlet end (5) and a plunger (6). The first cartridge (2) contains a first pharmaceutical component (7). The second cartridge (3) comprises a body (8) provided with an inlet end (17) and an outlet end (10). The second cartridge (3) contains a second pharmaceutical component (11). A non-invasive valve component (12) separates the first and second cartridges (2) and (3).

[0103] The non-invasive valve component (12) comprises a ball valve (13) which consists of a hollow piston (14) with a first end (15) adjacent the outlet end (5) of the first cartridge (2) and a second end (16) adjacent the inlet end (17) of the second cartridge (3).260493.000069The hollow piston (14) comprises a side wall (18) which generally forms a seal against the inner surface (19) of the body (8) of the second cartridge (3).

[0104] The first end (15) of the hollow piston (14) can include a circumferential recess (20) suitable for locating the outlet end (5) of the first cartridge (2). In the embodiment shown the outlet end (5) of the first cartridge (2) can include a circumferential shoulder (21) adapted to fit into the circumferential recess (20) of the first end (15) of the hollow piston (14). The second end (16) of the hollow piston (14) can include a pair of apertures (22) and (23). The outlet end (5) of the first cartridge (2) can include an orifice (24) within which sits a ball (25) which acts to seal the first cartridge (2).

[0105] In use, when the plunger (6) is depressed within the first cartridge (2) the increase in pressure will force the ball (25) out of the orifice (24), which causes the valve component (12) to open allowing the first pharmaceutical component (7), usually a fluid to flow from the first cartridge (2) through orifice (24), around ball (25), through apertures (22) and (23) and into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0106] Referring to FIGs. 2 (a) to (d) a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3) as hereinbefore described with reference to FIGs. 1 (a) to (d). The non-invasive valve component (12) comprises a ball valve (13) which consists of a hollow piston (14) with a first end (15) adjacent the outlet end (5) of the first cartridge (2) and a second end (16) adjacent the inlet end (17) of the second cartridge (3) as hereinbefore described.

[0107] However, the second end (16) of the hollow piston (14) comprises a separate plug component (16a) which can include a pair of apertures (22) and (23). In addition, the plug component (16a) can include a substantially central spigot (16b) which protrudes from plug component (16a) towards the outlet end (5) of the first cartridge (2).

[0108] In use, when the plunger (6) is depressed within the first cartridge (2) the first cartridge (2) slides towards the plug component (16a). When the spigot (16b) comes into contact with the ball (25), the ball (25) is displaced from orifice (24), which causes the valve component (12) to open allowing the first pharmaceutical component (7), usually a fluid to flow from the first cartridge (2) through orifice (24), around ball (25), through260493.000069apertures (22) and (23) and into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0109] Referring to FIGs. 3 (a) to (e), a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3), the first cartridge (2) being dimensioned so that it is slidable within the second cartridge (3) from a premixed position to a post-mixed position. The first cartridge (2) comprises a body (4) provided with an outlet end (5) and a plunger (6). The first cartridge (2) contains a first pharmaceutical component (7). The second cartridge (3) comprises a body (8) provided with an inlet end (17) and an outlet end (10). The second cartridge (3) contains a second pharmaceutical component (11). A non-invasive valve component (12) separates the first and second cartridges (2) and (3).

[0110] The non-invasive valve component (12) comprises a T-valve component (26). The T-valve component (26) consists of a pair of hollow pistons (27) and (28). A first hollow piston (27) is adjacent the outlet end (5) of the first cartridge (2) and a second hollow piston (28) is adjacent the inlet end (17) of the second cartridge (3). Each of the hollow pistons (27) and (28) comprises a side wall (29) and (30) respectively which generally forms a seal against the inner surface (19) of the body (8) of the second cartridge (3)-

[0111] The first hollow piston (27) can include a circumferential recess (31) suitable for locating the outlet end (5) of the first cartridge (2). In the embodiment shown the outlet end (5) of the first cartridge (2) can include a circumferential shoulder (21) adapted to fit into the circumferential recess (31) of the first hollow piston (27). The first hollow piston (27) is fitted with a stopper component (32) with an internal conduit (33) which is substantially coaxial with the longitudinal axis of the first cartridge (2). The internal conduit (33) is provided with a branched conduit (34) which seals against the side wall (29) of the first hollow piston (27).

[0112] The second hollow piston (28) is fitted with a second stopper component (35) with an internal conduit (36) which is substantially coaxial with the longitudinal axis of the first cartridge (2). The internal conduit (36) can include a branch (37) which seals against the side wall (30) of the second hollow piston (28).260493.000069

[0113] In use, when the plunger (6) is depressed within the first cartridge (2) the increase in pressure will force the stopper component (32) to protrude out of the first hollow piston (27). This movement causes the branched conduit (34) to be exposed and lose its seals against the side wall (29) of the first hollow piston (27) allowing the first pharmaceutical component (7), usually a fluid, to flow from the first cartridge (2) through internal conduit (33) and branched conduit (34) into the second hollow piston (28). Continued depression of the plunger (6) causes the second stopper component (35) to protrude out of the second hollow piston (28). This movement causes the branched conduit (37) to be exposed and lose its seal against the side wall (30) of the second hollow piston (28) allowing the first pharmaceutical component (7) to flow from the first cartridge (2) and first hollow piston (27) through internal conduit (36) and branched conduit (37) into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0114] Referring to FIGs. 4 (a) to (e), a pharmaceutical component-mixing delivery assembly (1) comprises first and second cartridges (2) and (3) as hereinbefore described.

[0115] An annular valve component (38) comprises a round stopper component (39) with a conduit external to the stopper. This is hereinafter referred to as an “annular valve”.

[0116] The annular valve component (38) consists of a pair of hollow pistons (40) and (41). A first hollow piston (40) is adjacent the outlet end (5) of the first cartridge (2) and a second hollow piston (41) is adjacent the inlet end (17) of the second cartridge (3). Each of the hollow pistons (40) and (41) comprises a side wall (42) and (43) respectively which generally forms a seal against the inner surface (19) of the body (8) of the second cartridge (3).

[0117] The first hollow piston (40) can include a circumferential recess (44) suitable for locating the outlet end (5) of the first cartridge (2) The first hollow piston (40) is fitted with a first stopper component (45) with a circumferential shoulder (46) adapted to fit into the outlet end (5) of the first cartridge (2) and seal it.

[0118] The first hollow piston (40) comprises a star shaped orifice (47) whilst the first stopper component (45) is substantially circular in cross section.

[0119] Similarly, the second hollow piston (41) comprises a star shaped orifice (48) and is fitted with a second stopper component (49). The second stopper component (49)260493.000069is substantially circular in cross section. However, the inner surface (43a) of the side wall (43) can include ridges (not shown) which enable the second stopper component (49) to form a seal.

[0120] It will be understood by the person skilled in the art that the shape of the orifices (47) and (48) and / or the first and second stopper components (45) and (49) may suitably be varied provided that the stopper (45) and (49) does not form a sealing fit within the orifice (47) and (48).

[0121] In use, when the plunger (6) is depressed within the first cartridge (2) the increase in pressure will force the first stopper component (45) out of the first cartridge (2). This movement allows the first pharmaceutical component (7), usually a fluid, to flow from the first cartridge (2) between the stopper component (45) and the side wall (42) of the piston (40) and through first orifice (47) into the second hollow piston (41). Continued depression of the plunger (6) causes the second stoper component (49) to move axially within the second hollow piston (41) away from the ridges (not shown). This movement causes the second stopper component (49) to lose its seal against the side wall (43) of the second hollow piston (41) allowing the first pharmaceutical component (7) to flow from the first cartridge (2) and first hollow piston (40) past the second stopper component (49) and through orifice (48) into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0122] Referring to FIGs. 5 (a) to (d) a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3), the first cartridge (2) being dimensioned so that it is slidable within the second cartridge (3) from a premixed position to a post-mixed position. An outer casing (97) is provided which houses the first and second cartridges (2) and (3). The first cartridge (2) comprises a body (4) provided with a sealed outlet end (50). The outer casing (97) comprises a sealed plunger end (51) and the plunger (6) protrudes through the sealed plunger end (51) of the outer casing (97). The first cartridge (2) contains a first pharmaceutical component (7). The second cartridge (3) comprises a body (8) provided with an inlet end (9) and an outlet end (10). The second cartridge (3) contains a second pharmaceutical component (11).

[0123] The plunger (6) can include a threaded surface (52) such that the threaded surface (52) is present along a predetermined portion of the length of the plunger (6). The260493.000069sealed plunger end (51) of the outer casing (97) can include a stopper (53) which includes an orifice (54) through which the plunger (6) passes and a frangible seal (98). The inner surface (55) of the orifice (54) can include a threaded surface (56) which corresponds to and engages with the threaded surface (52) of the plunger (6).

[0124] A plug component (57) separates the first and second cartridges (2) and (3). Said plug component (57) comprises a first seal (58) provided with a hollow needle (59) which extends either side of the first seal (58). A second seal (60) comprises a septum (61) provided with a guide channel (62) which, in use, is adapted to receive the needle (59) extending from the first seal (58).

[0125] In use, when the plunger (6) is turned within the orifice (54) of the stopper (53) in the outer casing (97) the frangible seal (98) is broken and the plunger (6) and the first cartridge (2) are pushed towards the second cartridge (3), causing the first cartridge (2) to disengage from the frangible seal (98). Continued turning of the plunger (6) causes the first cartridge (2) to slide towards the plug component (57) until the needle (59) pierces the sealed outlet end (50) of the first cartridge (2). Continued turning of the plunger (6) causes the needle (59) to pierce the septum (61) allowing the first pharmaceutical component (7), usually a fluid, to flow from the first cartridge (2) through the needle (59) and into the second cartridge (3) where it mixes with the second pharmaceutical component (11). Once the first and second pharmaceutical components (7) and (11) are mixed and the threaded surface (52) of the plunger (6) has passed through the orifice (54), the plunger (6) may be pushed in a conventional manner to administer the medicament solution to a patient.

[0126] Referring to FIGs. 6 and 7 (which includes FIGs. 6 (a) to (d) and FIGs. 7 (a) to (c)) a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3), the first cartridge (2) being dimensioned so that it is slidable within the second cartridge (3) from a pre-mixed position to a post-mixed position. The first cartridge (2) comprises a body (4) provided with an outlet end (5) and a plunger (6). The first cartridge (2) contains a first pharmaceutical component (7). The second cartridge (3) comprises a body (8) provided with an inlet end (17) and an outlet end (10). The second cartridge (3) contains a second pharmaceutical component (11). A non-invasive valve component (12) separates the first and second cartridges (2) and (3).260493.000069

[0127] The non-invasive valve component (12) comprises a spigot plug component (63) housed in a piston component (64). The piston component (64) is anchored to the first cartridge (2) by a lip (70). The spigot plug component (63) consists of a T-shaped component (65) with a first end (66) of narrower diameter forming a plug in the outlet end (5) of the first cartridge (2) and a second end (67) of wider diameter adjacent the inlet end (17) of the second cartridge (3). The dimensions of the second end (67) are such that it forms an “annular valve” component (68) with the side wall (69) of piston component (64).

[0128] In use, when the plunger (6) is depressed within the first cartridge (2) the increase in pressure will force the spigot plug component (63) away from outlet end (5) of the first cartridge (2), which creates a conduit (71) between T-shaped component (65) and the side wall (69) of piston component (64) through which the first pharmaceutical component (7), usually a fluid, can flow into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0129] Referring to FIGs. 8 and 9 (which includes FIGs. 8 (a) to (c) and FIGs. 9 (a) to (c)) a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3), the first cartridge (2) being dimensioned so that it is slidable within the second cartridge (3) from a pre-mixed position to a post-mixed position. The first cartridge (2) comprises a body (4) provided with an outlet end (5) and a plunger (6). The first cartridge (2) contains a first pharmaceutical component (7). The second cartridge (3) comprises a body (8) provided with an inlet end (17) and an outlet end (10). The second cartridge (3) contains a second pharmaceutical component (11). A non-invasive valve component (12) separates the first and second cartridges (2) and (3).

[0130] The non-invasive valve component (12) comprises a hollow plug component (72) housed in a piston component (73). The piston component (73) is anchored to the first cartridge (2) by a lip (74). The hollow plug component (72) consists of a stopper (75) provided with a T-shaped conduit (76) such that the inlet end (77) of the conduit is coaxial with the first and second cartridges (2) and (3) and the outlet end (78) of the conduit is perpendicular to the inlet end (77) of the conduit, i.e., diametrical to the stopper (75). The piston component (73) is also T-shaped such that the outlet end (79) of the piston component is of greater diameter than the inlet end (80) of the piston component (73).260493.000069Thus, the outlet end (78) of the conduit is capable of forming an “annular valve” component (81) with the side wall (82) of piston component (73).

[0131] In use, when the plunger (6) is depressed within the first cartridge (2) the increase in pressure will force the hollow plug component (72) away from outlet end (5) of the first cartridge (2), which opens the T-shaped conduit (76). Thus, the first pharmaceutical component (7), usually a fluid, can flow through the inlet end (77) of the conduit to the outlet end (78) of the conduit and between the side of the hollow plug component (72) and the side wall (82) of piston component (73) into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0132] Referring to FIGs. 10 and 11 (which includes FIGs. 10 (a) to (b) and FIGs. 11 (a) to (c)) a pharmaceutical component-mixing delivery assembly (1) comprises a first cartridge (2) and a second cartridge (3), the first cartridge (2) being dimensioned so that it is slidable within the second cartridge (3) from a pre-mixed position to a post-mixed position. The first cartridge (2) comprises a body (4) provided with an outlet end (5) and a plunger (6). The first cartridge (2) contains a first pharmaceutical component (7). The second cartridge (3) comprises a body (8) provided with an inlet end (17) and an outlet end (10). The second cartridge (3) contains a second pharmaceutical component (11). A non-invasive valve component (12) separates the first and second cartridges (2) and (3).

[0133] The non-invasive valve component (12) comprises an elongated piston (83). The piston (83) can include a plurality of external circumferential ribs (84) which form a seal between the side wall (85) of the piston (83) and the inner wall (86) of the second cartridge (3). The piston is also provided with terminal rib (87), comprising a circumferential rib located at the end (88) of the piston (83) nearest to the inlet end (17) of the second cartridge (3).

[0134] The region of the second cartridge (3) that contains the second pharmaceutical component (11) can include an aseptic mixing chamber (89). The length of the piston (83) will be dictated by how far back along the second cartridge (3) it has to move, which will in turn be dictated by the volume required for the mixing chamber (89). In use, as the plunger (6) is depressed and the piston (83) moves towards the inlet end (17) of the second cartridge (3), the mixing chamber (89) does not come into contact with the non-aseptic260493.000069inner wall (86) of the inlet end (17) of the second cartridge (3) and the sterility of the mixing chamber (89) is maintained at all times.

[0135] In some embodiments, the second cartridge (3) is dimensioned to accommodate a larger volume of reconstituted medicament. For example, the body (8) of the second cartridge (3) may define an internal volume configured to contain up to about 6 mb of reconstituted pharmaceutical component mixture following actuation of the pharmaceutical component-mixing delivery assembly. In such embodiments, the internal diameter of the second cartridge (3) and / or the axial length of the portion of the body (8) that defines the aseptic mixing chamber (89) are selected such that the desired reconstituted volume is provided while the aseptic mixing chamber (89) remains spaced from any non-aseptic inner wall (86) of the second cartridge (3) throughout movement of the piston component (94), which is discussed in greater detail below. By way of example, the second cartridge (3) can have an internal diameter of about 19 mm and an overall body length of about 46 mm. It will be appreciated that these dimensions can be varied according to the desired reconstituted volume and dose, provided that the length of the piston (83) and its stroke within the second cartridge (3) are selected so that, at all times during mixing and subsequent delivery, the aseptic mixing chamber (89) does not contact the non-aseptic inner wall (86) of the inlet end (17) of the second cartridge (3).

[0136] FIG. 12 is a cutaway perspective view of another non-invasive valve component (12) for a pharmaceutical component-mixing delivery assembly. The example shown in FIG. 12 is similar to the example shown and described with respect to FIGs. 6 and 7. In this example, the non-invasive valve component (12) comprises a piston component (94) that is anchored to the first cartridge (2) by a lip (92). The piston component (94) can include circumferential ribs (95) as defined above. A spigot plug component (93) is housed in the piston component (94). Similar to as described above, distal to the spigot plug component (93) is positioned a T-shaped conduit (96) into which the spigot plug component (93) can move when the plunger (6) is depressed within the first cartridge (2). The T-shaped conduit (96) is sized such that, when the first cartridge (2) pressure increases to move the spigot plug component (93) distally, an annular valve is created around the spigot plug component (93) and between the plug and the walls of the T-260493.000069shaped conduit (96). Fluid from first cartridge (2) can then exit the T-shaped conduit (96) through channels (99) formed at the distal end of the piston component (94).

[0137] FIGs. 13A-19 provide example implementations of a needle hub (100) that can be used with any of the aforementioned pharmaceutical component-mixing delivery assemblies (1). The prior disclosure provided various solutions for reconstitution devices. One aspect of those devices is to take the reconstituted medicament and deliver said reconstituted medicament as needed (e.g., by injecting a patient or, more likely, by delivering the fluid from the injector into another medical container or fluid delivery device). More information about delivery mechanisms and needle connections is provided below. FIGs. 13A-19 show an example needle hub (100) that can be used to attach to an outer cartridge (e.g., second cartridge (3)) proximate the outlet end (10) to deliver the medicament.

[0138] Referring now to FIG. 13 A, a needle hub (100) includes a transfer needle (102), which can be attached to or can extend from the needle hub (100). The transfer needle (102) will be positioned such that, once assembled, the transfer needle (102) will be pointed retrograde such that it is pointed toward a pierceable seal of second cartridge (3) (see FIGs. 15A and 15B for reference). FIG. 13B shows the needle hub (100) and the transfer needle (102) assembled. It will be appreciated that the transfer needle (102) can be a separate component from the needle hub (100) and which is co-molded, insert molded, or glued to the needle hub (100). In other examples the transfer needle (102) can be a molded spike that is integrated with the needle hub (100).

[0139] The needle hub (100) includes one or more attachment features that allows the hub to attach to a housing (108), as will be described below. The attachment features can be one or more snappers (104) that engage the housing (108), as shown. A snapper (104) is a deflectable extension with a protrusion or tab at one end, and the protrusion or tab can engage with one or more snapper engagement locations of the housing (108) (see, e.g., FIGs. 14A and 14C). The needle hub (100) also includes a needle connector (106) that can connect to one or more delivery needles (e.g., a delivery needle (120) as in FIG.15B). The needle connector (106) can be a luer lock connection, a luer slip connection, or the like. The needle connector (106) can be one side of a male-to-male or female-to-female connection that enables the needle hub (100) to fluidly connect the pharmaceutical260493.000069component-mixing delivery assembly (1) to another delivery device. In some examples, the needle hub (100) can be used in intramuscular injection, and as such the needle connector (106) can be sized and / or shaped to accommodate a delivery needle (120) that can be used for the intramuscular injection, for example and not limitation a 20 to 25 gauge needle. In some examples, the needle hub (100) can be used for subcutaneous injection, and as such the needle connector (106) can be sized and / or shaped to accommodate a delivery needle (120) that can be used for the subcutaneous injection, for example and not limitation a 25 to 30 gauge needle. In some examples, the needle hub (100) can be used in connecting to an intravenous (IV) line, and as such the needle connector (106) can be sized and / or shaped to connect to a connector on the IV line.

[0140] A housing (108) is shown in FIG. 14A. The housing (108) can include visualization windows (110) that can enable an operator to see inside to view the first cartridge (2), second cartridge (3), or the pharmaceutical components therein while reconstitution is being performed. At a distal end of the housing (108) (distal being down in FIG. 14A), the housing (108) can include longitudinal grooves (see FIG. 14C labeled as grooves (109)) that extend from the end of the housing (108) one or more snapper engagement locations in the housing (108). When the needle hub (100) is being assembled into the distal end of the housing (108), the snappers (104) can slide down a respective longitudinal grooves (109) and snap into place into the one or more snapper engagement locations. The housing (108) can include first snapper engagement locations (112) positioned distally, and second snapper engagement locations (114) positioned more proximally. As will be described in greater detail below, the snappers (104) can be engaged in the first snapper engagement locations (112) when the needle hub (100) is at an initial position. The pressure on the needle hub (100) distally, for example by applying the delivery needle (120) (see FIG. 15B) to the needle connector (106), can cause the snappers (104) to disengage from the first snapper engagement locations (112) and engage within the second snapper engagement locations (114). At this location, the transfer needle (102) translates proximally as well and extends through the pierceable seal (116) of the second cartridge (3) (also see FIG. 15B for illustration). The snapper engagement locations (112), (114) can be apertures or depressions in the body of the housing (108).260493.000069

[0141] In other embodiments, the housing (108) can be formed from a translucent or transparent material that does not require visualization windows (110), which could provide the benefit of simplifying the manufacturing processes as well as providing for a more cohesive outer shell. A see-through housing (108) would also allow for the use of a fully wrapped sleeve or sticker that could allow for additional graphics to promote correct usage of the syringe assembly. The fully wrapped sleeve could also be the seal (170) shown in FIG. 22C, for example.

[0142] FIG. 14B shows a housing (108) with a needle hub (100) connected thereto. The needle hub (100) can also include centering guides (105) extending similar to the snappers (104) but do not slide in longitudinal grooves (109). Instead, the centering guides (105) can have an outwardly-deflected bias such that they engage an interior surface of a distal end of the housing (108). FIG. 14C is a cross-sectional view of the housing (108) assembly shown in FIG. 14B. FIG. 14C provides a view of the longitudinal grooves (109) that the one or more snappers (104) can slide through from their first snapper engagement locations (112) to their second snapper engagement locations (114).

[0143] FIG. 15A is a detailed view of a needle hub (100) assembled to a housing (108) prior to attaching a delivery needle (120). The needle hub (100) is positioned near the outlet end (10) of the second cartridge (3), such that the outlet end (10) abuts a stop (118) in the needle hub (100). The transfer needle (102) is positioned toward the pierceable seal (116) of the second cartridge (3). At this position, the one or more snappers (104) can be engaged within their more distal first snapper engagement locations (112) (see FIG. 14B). FIG. 15B is a detailed view of the assembly of FIG. 15A after attaching the delivery needle (120) to the needle hub (100). Axial pressure upon the distal end of the needle hub (100) can cause the needle hub (100) to translate proximally ( / .<?., to the right in the view of FIG. 15B) along a longitudinal axis L-L of the housing (108), moving the snappers (104) through their longitudinal grooves (109) (see FIG. 14C) from the first snapper engagement locations (112) to the second snapper engagement locations (114), and thereby moving the transfer needle (102) through the pierceable seal (116). In some examples, this axial force can be provided by attaching the delivery needle (120) onto the needle connector (106), thereby priming the device to be ready to inject. In other examples, the force of a user inserting the tip of the delivery needle (120) through skin260493.000069can be sufficient to disengage the one or more snappers (104) from their first snapper engagement locations (112) so as to translate to the second snapper engagement locations (114). In yet other examples, the amount of force required to disengage the one or more snappers (104) from their first snapper engagement locations (112) can be high enough to prevent inadvertent proximal movement of the needle hub (100), and as such a user must provide sufficient, and purposeful force to move the needle hub (100).

[0144] FIG. 16A shows the step of assembling a pharmaceutical component-mixing delivery assembly (1) with a housing (108) comprising a needle hub (100). The pharmaceutical component-mixing delivery assembly (1) can be any of the aforementioned assemblies comprising a first cartridge (2) and a second cartridge (3), and once those cartridges are assembled, they can be inserted into the housing (108) at the opposite end from where the connected needle hub (100) is connected. FIG. 16B shows the pharmaceutical component-mixing delivery assembly (1), housing (108), and needle hub (100) assembled.

[0145] FIG. 17A shows the step of adding an end cap (124) to the assembly shown in FIG. 16B. The end cap (124) can be added to contain the assembled pharmaceutical component-mixing delivery assembly (1) within the housing (108). The end cap (124) includes a plunger aperture (126) that can accept a plunger (6) (see FIG. 18A). FIG. 17B shows the pharmaceutical component-mixing delivery assembly (1), housing (108), and needle hub (100) assembly with the end cap (124) connected.

[0146] FIG. 18A shows the step of adding the plunger (6) to the assembly shown in FIG. 17B. The plunger (6) is inserted into the first cartridge (2) via the plunger aperture (126), and a distal end of the plunger (6) can be attached to a stopper within the first cartridge (2). FIG. 18B shows the pharmaceutical component-mixing delivery assembly (1), housing (108), and needle hub (100) assembly, end cap (124) and plunger (6) all assembled. At the implementation shown in FIG. 18B, the device is ready for adding a delivery needle (120).

[0147] FIG. 19 shows a fully assembled device with a needle hub (100) after delivering a reconstituted medicament using the device. The view clearly shows the location of a snapper (104) having transitioned to a second snapper engagement locations (114). Any260493.000069of the embodiments described herein can include a safety cap (122) to cover the delivery needle (120), as will be appreciated.

[0148] It will also be appreciated that any of the needle hub (100) assemblies described herein and related systems can be used in any environment in which a user needs to reconstitute or resuspend second pharmaceutical component (11) (e.g., a liquid or a solid, such as a powder, medicament) with the help of first pharmaceutical component (7) (e.g., a diluent) within pharmaceutical component-mixing delivery assembly (1). For example, pharmaceutical component-mixing delivery assembly (1) can be stored separately from needle hub (100), and when needed, a user can grab the pharmaceutical componentmixing delivery assembly (1), insert it into needle hub (100) as described herein, reconstitute / resuspend the medicament, and then deliver. As such, it is contemplated that the pharmaceutical component-mixing delivery assembly (1) could be stored in a refrigerated state before being used with needle hub (100). It is also contemplated that the pharmaceutical component-mixing delivery assembly (1) can be stored inside of the needle hub (100). In any case, the systems described herein provide good solutions for emergency care, for example in military use, paramedic or emergency medical services use, and the like.

[0149] FIG. 20 is a flowchart for an example method (2000) for using a syringe assembly. Method (2000) includes connecting (2005) a needle hub to a distal end of a housing. Method (2000) includes inserting (2010) a pharmaceutical component-mixing delivery assembly into a proximal end of the housing. Method (2000) includes securing (2015) the pharmaceutical component-mixing delivery assembly within the housing. Method (2000) includes moving (2020) the needle hub from a first position with respect to the housing to a second position with respect to the housing, such that a transfer needle of the needle hub moves proximally toward the pharmaceutical component-mixing delivery assembly. Method (2000) includes piercing (2025), in response to proximal movement of the transfer needle, a seal of the pharmaceutical component-mixing delivery assembly with the transfer needle.

[0150] FIGs. 21 A-21F show steps to fill a pharmaceutical component-mixing delivery assembly (1). The examples shown in FIGs. 21A-21F depict the steps of filling an assembly comprising a first cartridge (2), a second cartridge (3), and the non-invasive260493.000069valve component (12) shown in and described with respect to FIG. 12. It will be appreciated, however, that other examples of the non-invasive valve component (12) systems described herein can be supplemented in place of the examples shown in FIG.12. Referring now to the method steps of filling the pharmaceutical component-mixing delivery assembly (1), FIG. 21A shows the step of adding a spigot plug component (93) to a first cartridge (2). The spigot plug component (93) is inserted to seal the distal end (in a down direction in FIG. 21A) of the first cartridge (2). In FIG. 21B, a first pharmaceutical component (7) is added to the first cartridge (2). As described herein, the first pharmaceutical component (7) can be a liquid diluent.

[0151] FIG. 21C shows the step of adding a plunger stopper (128) to the open, proximal end of the first cartridge (2). Because the distal end of the first cartridge (2) includes the spigot plug component (93), inserting the plunger stopper (128) into the first cartridge (2) could cause a positive pressure within the cartridge that could push out the spigot plug component (93). Accordingly, to ensure the spigot plug component (93) is not disengaged from the first cartridge (2) when inserting the plunger stopper (128), the step shown in FIG. 29C can be performed under vacuum. In other words, after adding the first pharmaceutical component (7), the first cartridge (2) can be placed into a vacuum chamber along with the plunger stopper (128) to insert the plunger stopper (128).

[0152] FIG. 21D shows the step of adding a second pharmaceutical component (11) into a distally-sealed second cartridge (3). The second cartridge (3) is sealed by a cartridge cap (115) inserted into the distal end of the second cartridge (3). The cartridge cap (115) comprises the aforementioned pierceable seal (116) (see FIGs. 15A and 15B for reference). Since the distal end of the second cartridge (3) is closed, the second pharmaceutical component (11) can be inserted into the rear (z.e., open proximal end) of the second cartridge (3).

[0153] FIG. 2 IE shows the step of adding a piston component (94) to the first cartridge (2). As described above, a non-invasive valve component (12) can include the piston component (94) and the spigot plug component (93). The non-invasive valve component (12) separates the first and second cartridges (2) and (3). The piston component (94) plus the spigot plug component (93) work as a one-way valve, allowing the first pharmaceutical component (7) to flow distally to mix with the second pharmaceutical260493.000069component (11) in the second cartridge (3), but preventing the mixed first / second pharmaceutical components to flow proximal back into the second cartridge (3). FIG. 21E simply shows the step of adding the piston component (94) to the distal end of the first cartridge (2) that already includes the spigot plug component (93) (see FIG. 21A).

[0154] FIG. 21F shows the step of adding the first cartridge (2), with the positioned piston component (94), into the rear (z.e., proximal) end of the second cartridge (3). Because the distal end of the second cartridge (3) includes the cartridge cap (115), inserting the first cartridge (2) into the second cartridge (3) could cause a positive pressure to build within the second cartridge (3), making it difficult to insert the first cartridge (2). Accordingly, the step shown in FIG. 2 IF can be performed under vacuum. In other words, the second cartridge (3) can be placed into a vacuum chamber along with the first cartridge (2) such that the first cartridge (2), with the positioned piston component (94), can be inserted into the rear (z.e., proximal) end of the second cartridge (3). After the step shown in FIG. 2 IF, the assembled construct shown therein can be inserted into housing (108) assembled with the needle hub (100) (see FIG. 16A).

[0155] FIG. 22 is a flowchart for an example method (2200) for filling a pharmaceutical component-mixing delivery assembly (1) via a rear-fill method. Method (2200) includes inserting (2205) a spigot plug component (90) into a distal end of a first cartridge (2). Method (2200) includes filling (2210) the first cartridge (2), via an open proximal end of the first cartridge (2), with a first pharmaceutical component (7). Method (2200) includes inserting (2215), with the first cartridge (2) in a vacuum, a plunger stopper (128) into the open proximal end of the first cartridge (2) to seal the first pharmaceutical component (7). Method (2200) includes inserting (2220) a cartridge cap (115) onto a distal end of a second cartridge (3), the cartridge cap (115) comprising a pierceable seal (116). Method step (2220) is shown in dashed lines as it is an optional step; the cartridge cap (115) may come pre-loaded on the second cartridge (3). Method (2200) includes filling (2225) the second cartridge (3), via an open proximal end of the second cartridge (3), with a second pharmaceutical component (11). Method (2200) includes positioning (2230) a piston component (94) onto the distal end of the first cartridge (2). Method (2200) includes inserting (2235), with the first cartridge (2) and the second cartridge (3) in a vacuum, the distal end of the first cartridge (2) into the open proximal end of the second cartridge (3)260493.000069to seal the second pharmaceutical component (11). Method (2200) can end after step (2235), or additional steps can be performed according to the present disclosure.

[0156] FIGs. 23A-23G show steps to fdl a pharmaceutical component-mixing delivery assembly (1). The examples shown in FIGs. 23A-23G depict the steps of filling an assembly comprising a first cartridge (2), a second cartridge (3), and the non-invasive valve component (12) shown in and described with respect to FIG. 12. It will be appreciated, however, that other examples of the non-invasive valve component (12) systems described herein can be supplemented in place of the examples shown in FIG.12. Referring now to the method steps of filling the pharmaceutical component-mixing delivery assembly (1), FIG. 23A shows the step of adding a spigot plug component (93) to a first cartridge (2). The spigot plug component (93) is inserted to seal the distal end (down in FIG. 23A) of the first cartridge (2). In FIG. 23B, a first pharmaceutical component (7) is added to the first cartridge (2). As described herein, the first pharmaceutical component (7) can be a liquid diluent.

[0157] FIG. 23C shows the step of adding a plunger stopper (128) to the open, proximal end of the first cartridge (2). Because the distal end of the first cartridge (2) includes the spigot plug component (93), inserting the plunger stopper (128) into the first cartridge (2) could cause a positive pressure within the cartridge that could push out the spigot plug component (93). Accordingly, to ensure the spigot plug component (93) is not disengaged from the first cartridge (2) when inserting the plunger stopper (128), the step shown in FIG. 23C can be performed under vacuum. In other words, after adding the first pharmaceutical component (7), the first cartridge (2) can be placed into a vacuum chamber along with the plunger stopper (128), and the plunger stopper (128) can be inserted.

[0158] FIG. 23D shows the step of adding a piston component (94) to the first cartridge (2). As described above, a non-invasive valve component (12) can include the piston component (94) and the spigot plug component (93). The non-invasive valve component (12) separates the first and second cartridges (2) and (3). The piston component (94) in combination with the spigot plug component (93) work as a one-way valve, allowing the first pharmaceutical component (7) to flow distally to mix with the second pharmaceutical component (11) in the second cartridge (3), but preventing the mixed first / second260493.000069pharmaceutical components to flow proximal back into the second cartridge (3). FIG.23D simply shows the step of adding the piston component (94) to the distal end of the first cartridge (2) that already includes the spigot plug component (93) (see FIG. 23 A).

[0159] FIG. 23D shows the step of adding the first cartridge (2), with the positioned piston component (94), into the rear (z.e., proximal) end of the second cartridge (3). In this example, the distal end / tip of the second cartridge (3) is not covered or closed, so the first cartridge (2), with the positioned piston component (94), can be inserted without positive pressure building in the second cartridge (3). FIG. 23F shows inverting the assembly shown in FIG. 23E such that the open distal tip of the second cartridge (3) is positioned upwardly. Then, a second pharmaceutical component (11) can be added into the open distal tip of the second cartridge (3). FIG. 23G shows sealing the distal tip of the second cartridge (3) with a cartridge cap (115). After the step shown in FIG. 23G, the assembled construct shown herein can be inserted into housing (108) assembled with the needle hub (100) (see FIG. 16A).

[0160] FIG. 24 is a flowchart for an example method (2400) for filling a pharmaceutical component-mixing delivery assembly (1) via a tip-fill method. Method (2400) includes inserting (2405) a spigot plug component (90) into a distal end of a first cartridge (2). Method (2400) includes filling (2410) the first cartridge (2), via an open proximal end of the first cartridge (2), with a first pharmaceutical component (7). Method (2400) includes inserting (2415), with the first cartridge (2) in a vacuum, a plunger stopper (128) into the open proximal end of the first cartridge (2) to seal the first pharmaceutical component (7). Method (2400) includes positioning (2420) a piston component (94) onto the distal end of the first cartridge (2). Method (2400) includes inserting (3225) the distal end of the first cartridge (2) into a proximal end of a second cartridge (3). Method (2400) includes inverting (2430) the second cartridge (3) such that an open distal end is positioned upwardly. Method (2400) includes filling (2435) the open distal end with a second pharmaceutical component. Method (2400) includes sealing (2440) the second pharmaceutical component within the second cartridge with a cartridge cap. Method (2400) can end after step (2440), or additional steps can be performed according to the present disclosure.260493.000069

[0161] In any example described herein, the pharmaceutical component-mixing delivery assembly (1) can deliver, for example, a hydrocortisone sodium succinate sodium salt, hydrocortisone phosphate, and / or hydrocortisone acetate. However, as will be appreciated, other active components (such as those listed, supra) can be included. In some examples, the active components can be spray-dried or lyophilized, and that spray-dried or lyophilized product can be placed in the second cartridge (3). In certain examples, there can be advantages to spray drying the active component (e.g., hydrocortisone sodium succinate sodium salt). Spray drying can be a simple, singular process from solution to powder, whereas lyophilization requires additional milling or micronization. Spray drying provides consistent particle size and flow properties, and there is a possibility for particle engineering to adjust size distribution if necessary. The particles made by the spray drying process can be of any size, including nano-, micro-, submicro-, and macro-sized particles. Generally, the particles are between about 0.5 pm to 50 pm in diameter, or between 1 pm and 10 pm in diameter. As such, this disclosure also provides solutions for spray drying the pharmaceutical component (e.g., hydrocortisone sodium succinate sodium salt) to include in the second cartridge (3).

[0162] FIGs. 25A-25C are cross-sectional views showing use of a syringe assembly.

[0163] Referring to FIG. 25 A, the needle hub (100) is connected to a distal end of the housing (108). The first cartridge (2) and the second cartridge (3) are inserted into and secured within a proximal end of the housing (108).

[0164] Referring to FIG. 25B, when the plunger (6) is depressed within the first cartridge (2), the increase in pressure will force the spigot plug component (93) away from outlet end of the first cartridge (2), which opens the conduit (96). Thus, the first pharmaceutical component (7), usually a fluid, can flow through the inlet end of the conduit (96) to the outlet end of the conduit (96) and between the side of the spigot plug component (93) and the side wall of piston component (94) into the second cartridge (3) where it mixes with the second pharmaceutical component (11).

[0165] Referring to FIG. 25C, the needle hub (100) is moved from a first position (see position of the needle hub ( 100) in FIG. 25B) with respect to the housing ( 108) to a second position (see position of the needle hub (100) in FIG. 25C) with respect to the housing (108), such that the transfer needle (102) of the needle hub (100) moves proximally260493.000069toward the pharmaceutical component-mixing delivery assembly. This proximal movement of the transfer needle (102) results in the piercing of the seal (116) of the pharmaceutical component-mixing delivery assembly with the transfer needle (102). The transition between the position shown in FIG. 25B and that shown in FIG. 25C also shows the piston component (94) being pushed further distally by plunger (6). This distal movement of the piston component (94) also drives the reconstituted pharmaceutical component (7, 11) through the transfer needle (102).

[0166] FIG. 26 is a perspective view showing an alternative assembled syringe assembly (200) in accordance with aspects of the present disclosure. FIGs. 27A-27D show the alternative syringe assembly (200) of FIG. 26 in use. Except where noted below, it should be appreciated that the components described in this example can take a similar form and / or function as their respective counterparts in previous examples. Therefore, details germane to this example are the focus of the following section.

[0167] In contrast with the previous examples, the syringe assembly of FIG. 26 provides multiple pharmaceutical component-mixing delivery assemblies, such as two pharmaceutical component-mixing delivery assemblies (201 A) and (20 IB), that are adjacently arranged within a housing (308), thus enabling a higher volume (e.g., 1 mL or greater per delivery assembly, meaning 2 mL or greater total volume) of reconstituted pharmaceutical component (z.e., the pharmaceutical component-mixing delivery assemblies (201 A) and (20 IB) have an identical composition) to be delivered through a single delivery needle or different reconstituted pharmaceutical components (i.e., the pharmaceutical component-mixing delivery assemblies (201A) and (201B) have a different composition from one another) to be simultaneously delivered through a single delivery needle. In some examples, the total reconstituted pharmaceutical component delivered through the transfer needle / a convergence conduit (306C) (discussed in greater detail below) can be equal to or exceed 6 mL.

[0168] It is noted that, although two pharmaceutical component-mixing delivery assemblies (201A) and (201B) are shown and described, the present disclosure contemplates any appropriate number (e.g., three, four, or more) of pharmaceutical component-mixing delivery assemblies provided together in a housing to deliver an even higher total volume of reconstituted pharmaceutical component, with the total number of260493.000069assemblies being a multiplier for the total amount of reconstituted pharmaceutical component delivered relative to the volume of a single pharmaceutical componentmixing delivery assembly.

[0169] A first pharmaceutical component-mixing delivery assembly (201A) is configured similar to that of the above examples and comprises a first cartridge (202 A) and a second cartridge (203 A), the first cartridge (202A) being dimensioned so that it is slidable within the second cartridge (203 A) from a pre-mixed position to a post-mixed position. The first cartridge (202A) contains a first pharmaceutical component (207A). The second cartridge (203 A) contains a second pharmaceutical component (211 A). Those skilled in the art will appreciate that the pharmaceutical components described in the present example can encompass any of the prior examples. A non-invasive valve component separates the first and second cartridges (202A) and (203A) and can be configured similarly to that of the example of FIG. 12.

[0170] Similarly, a second pharmaceutical component-mixing delivery assembly (20 IB) is configured to similar to that of the above examples comprises a third cartridge (202B) and a fourth cartridge (203B), the third cartridge (202B) being dimensioned so that it is slidable within the fourth cartridge (203B) from a pre-mixed position to a postmixed position. The third cartridge (202B) contains a third pharmaceutical component (207B). The fourth cartridge (203B) contains a fourth pharmaceutical component (21 IB). In some examples, these components mirror that of the first pharmaceutical componentmixing delivery assembly (201 A); in other examples, they have differing compositions. A non-invasive valve component separates the third and fourth cartridges (202B) and (203B) and can be configured similarly to that of the example of FIG. 12.

[0171] For example, as seen in FIG. 27A, respective spigot plug components (293A) and (293B) and respective piston components (294A) and (294B) can be provided as the non-invasive valve components. The piston components (294A) and (294B) are respectively anchored to the first cartridge (202A) and the third cartridge (202B) by a lip or annular ridge. The piston components (294A) and (294B) can include circumferential ribs (295A) and (295B) as defined above. The spigot plug components (293 A) and (293B) are respectively housed in the piston components (294A) and (294B). Similar to as described above with respect to the spigot plug component (93) of FIG. 12, distal to the260493.000069respective spigot plug components (293 A) and (293B) are positioned T-shaped conduits (296A) and (296B) into which the spigot plug components (293A) and (293B) can respectively move when the plunger (206) is depressed, which pushes plunger rods (206A) and (206B) of the plunger (206) into the first and third cartridges (202A) and (202B). The T-shaped conduits (296A) and (296B) are sized such that, when the first and third cartridges (202A) and (202B) pressures increase to move the spigot plug components (293 A) and (293B) distally, an annular valve is created around the spigot plug components (293 A) and (293B) and between the plug and the walls of the T-shaped conduits (296A) and (296B). Fluid from first cartridge (202A) can then exit the T-shaped conduit (296A) through channels formed at the distal end of the piston component (294A) (see channels (99) in FIG. 12 for reference), and fluid from third cartridge (202B) can then exit the T-shaped conduit (296B) through channels formed at the distal end of the piston component (294B) (see channels (99) in FIG. 12 for reference).

[0172] Plunger stoppers (328A) and (328B) (similar to plunger stopper (128) described above) are disposed within the open, proximal end of the first cartridge (202A) and the third cartridge (202B), respectively. Because the distal end of the first and third cartridges (202A) and (202B) include the spigot plug components (293 A) and (293B), inserting the plunger stoppers (328A) and (328B) could cause a positive pressure within the cartridge that could push out the spigot plug components (293A) and (293B). Accordingly, to ensure the spigot plug components (293 A) and (293B) are not disengaged from the first cartridge (202A) and the third cartridge (202B), inserting the plunger stoppers (328A) and (328B) can be performed within a vacuum. In other words, and for example, after adding the first pharmaceutical component (207A), the first cartridge (202A) can be placed into a vacuum chamber along with the plunger stopper (328A) to insert the plunger stopper (328A), with a similar process followed for the third cartridge (202B).

[0173] A housing (308) is shown in FIG. 26 and contains the first, second, third, and fourth cartridges (202A), (202B), (203A), and (203B). The housing (308) can include visualization windows (such as visualization windows (110) described above with respect to FIG. 14A) that can enable an operator to see inside to view the first cartridge (202A), second cartridge (203A), third cartridge (202B), fourth cartridge (203B) or the pharmaceutical components therein while reconstitution is being performed. In other260493.000069embodiments, the housing (308) can be formed from a translucent or transparent material that does not require visualization windows, which could provide the benefit of simplifying the manufacturing processes as well as providing for a more cohesive outer shell.

[0174] With continued reference to FIG. 26, a needle hub (300) includes a pair of transfer needles (302A) and (302B), which can be attached to or can extend from the needle hub (100). In FIG. 26, the needle hub (300) is partially cut away to illustrate the transfer needle structure disposed therewithin. The transfer needles (302A) and (302A) will be positioned such that, once assembled, the transfer needles (302A) and (302B) will be pointed retrograde such that they respectively point towards a pierceable seal (316A) of second cartridge (203 A) and a pierceable seal (316B) of fourth cartridge (203B). It will be appreciated that the transfer needles (302A) and (302B) can be separate components from the needle hub (300) and which are co-molded, insert molded, or glued to the needle hub (300). In other examples, the transfer needle (302A) and (302B) can be molded spikes that is integrated with the needle hub (300).

[0175] A needle hub (300) is provided that includes one or more attachment features that allows the hub (300) to attach to the housing (308). The attachment features can be, e.g., one or more snappers or detents that engage the housing (308), such as those described above (e.g., snappers 104). The needle hub (300) also includes a needle connector (306) (also referred to herein as an outlet) that can connect to one or more delivery needles (e.g., a delivery needle (120) as in FIG. 15B). The needle connector (306) can be a luer lock connection, a luer slip connection, or the like. The needle connector (306) can be one side of a male-to-male or female-to-female connection that enables the needle hub (300) to fluidly connect the first and second pharmaceutical component-mixing delivery assemblies (201 A) and (20 IB) to another delivery device. In some examples, the needle hub (300) can be used in intramuscular injection, and as such the needle connector (306) can be sized and / or shaped to accommodate a delivery needle (120) (FIG. 15B) that can be used for the intramuscular injection, for example and not limitation a 20 to 25 gauge needle. In some examples, the needle hub (300) can be used for subcutaneous injection, and as such the needle connector (306) can be sized and / or shaped to accommodate a delivery needle (120) that can be used for the subcutaneous260493.000069injection, for example and not limitation a 25 to 30 gauge needle. In some examples, the needle hub (300) can be used in connecting to an intravenous (IV) line, and as such the needle connector (306) can be sized and / or shaped to connect to a connector on the IV line.

[0176] FIG. 27 also shows a needle hub (300) assembled to the housing (308) prior to attaching a delivery needle. The needle hub (300) is positioned near the outlet ends of the second cartridge (203 A) and the fourth cartridge (203B), such that the outlet end abuts a stop in the needle hub (300) (e.g., similar to the stop (118) described above). The needle hub (300) includes two transfer needles (302A) and (302B) that are respectively positioned toward the pierceable seal (316A) of the second cartridge (203 A) and the pierceable seal (316B) of the fourth cartridge (203B). Axial pressure upon the distal end of the needle hub (300) can cause the needle hub (300) to translate proximally (z.e., up and to the right in the view of FIG. 26) along a longitudinal axis L-L of the housing (308), thereby moving the transfer needles (302A) and (302B) through their respective pierceable seals (316A, 316B). In some examples, this axial force can be provided by attaching the delivery needle onto the needle connector (306), thereby priming the device to be ready to inject. In other examples, the force of a user inserting the tip of the delivery needle through skin can be sufficient to enable this action. In yet other examples, the amount of force required to disengage the needle hub (300) from its position can be high enough to prevent inadvertent proximal movement of the needle hub (300), and as such a user must provide sufficient, and purposeful force to move the needle hub (300).

[0177] The needle hub (300) further includes a convergence conduit (302C) that fluidically connects the two transfer needles (302A) and (302B) together, such that they are fluidly connected with the delivery needle and connected to the needle connector (306) via the convergence conduit (302C). As seen particularly in FIG. 26, the convergence conduit (302C) is approximately parallel to proximal sections of the transfer needles (302A) and (302B). Each transfer needle (302A) and (302B) can have a bend (303A) and (303B) that redirects a path of the respective transfer needle (302A) and (302B) so as to form a junction at the convergence conduit (302C). In some examples, the transfer needles (302A) and (302B) do not include the bends (303 A) and (303B), but instead the one end of the transfer needles (302A) and (302B) that pierce the pierceable260493.000069seals (316A, 316B) can be in fluid communication with the convergence conduit (302C) via channels made in the needle hub (300). In this instance, the transfer needles (302A) and (302B) can be substantially straight / cylindrical, and fluidly connect directly to the convergence conduit (302C) via the channels formed into the body of the needle hub (300).

[0178] As those skilled in the art will appreciate, in certain embodiments that include more than two pharmaceutical component-mixing delivery assemblies, the needle hub (300) would have a corresponding number of transfer needles, each associated with a respective pharmaceutical component-mixing delivery assembly. The transfer needles would all either directly converge at the convergence conduit (302C) (as seen in FIG. 26), or would all be in direct fluid connection with the convergence conduit (302C) via, e.g., channels made in the needle hub (300), as discussed in the directly preceding paragraph.

[0179] Referring to FIGs. 27A-27B, when the plunger (206) is pushed distally (denoted by the arrow in FIG. 27 A), the plunger rods (206A) and (206B) are depressed within the first cartridge (202A) and the third cartridge (202B), respectively. The increase in pressure due to movement of the plunger stoppers (328A) and (328B) force the spigot plug components (293 A) and (293B) away from outlet end of the first cartridge (202A) and the third cartridge (202B), which opens the respective conduits (296A) and (296B). Thus, the first and third pharmaceutical components (207A) and (207B), usually a fluid, can flow through the inlet end of the respective conduits (296A) and (296B) to the outlet end of the respective conduits (296A) and (296B) and between the side of the spigot plug components (293A) and (293B) and the side wall of piston components (294A) and (294B) into the second cartridge (203 A) and fourth cartridge (203B), respectively, where they respectively mix with the second pharmaceutical component (211 A) and the fourth pharmaceutical component (21 IB), resulting in reconstituted pharmaceutical components (207A, 211A) and (207B, 21 IB).

[0180] Referring to FIGs. 27B-27C, the needle hub (300) is moved a predetermined distance (AX) from a first position (see position of the needle hub (100) in FIG. 27B) with respect to the housing (308) to a second position (see position of the needle hub (300) in FIG. 27C) with respect to the housing (308), such that the transfer needles (302A) and (302B) of the needle hub (300) moves proximally toward the pharmaceutical260493.000069component-mixing delivery assemblies (201A) and (201B). This proximal movement of the transfer needles (302A) and (302B) results in the piercing of the seals (316A) and (316B) with the transfer needles (302A) and (302B).

[0181] As seen from FIGs. 27C-27D, further distal movement of the plunger (206) (see the arrow in FIG. 27C) drives the reconstituted pharmaceutical component (207A, 211 A) and (207B, 21 IB) through the respective transfer needles (302A) and (302B) (which, thus, form portions of a fluidic path), mixing and / or converging at and passing through the convergence conduit (302C) (which forms another portion of the fluidic path), through a needle connector (306) (also referred to herein as an outlet), and through the delivery needle. In all of these aforementioned examples, it is noted that convergence of the reconstituted pharmaceutical components (207A, 211A) and (207B, 21 IB) occurs prior to exit out of the outlet / needle connector (306). It is, therefore, important to note that this design differs significantly from prior structures that employ dual chamber applicators. In previous designs, such as those used in epoxy applicators, two separate components were recombined outside the cylinders. This means that no mixing occurred within the applicator itself, which was crucial to prevent unwanted reactions inside them.

[0182] In contrast, the present disclosure allows for mixing to occur entirely within the pharmaceutical component-mixing delivery assemblies (201A) and (201B), followed by a secondary convergence outside the pharmaceutical component-mixing delivery assemblies (201A) and (201B). This feature enables the simultaneous reconstitution of two different components, which are then combined externally. This approach is beneficial when internal mixing is undesirable, but external combination is acceptable. By way of example, Drug A can be combined in the first pharmaceutical componentmixing delivery assembly (201 A), while Drug B can be combined in the second pharmaceutical component-mixing delivery assembly (20 IB). Then, Drugs A and B can be combined / converged distal to the delivery assemblies (201 A) and (20 IB) so that neither Drug A nor Drug B interacts with the other drug’s delivery assembly (201 A) or (201B).

[0183] FIGs. 28A-28D and FIGs. 29A-29D depict various views of two other exemplary spigot plug components (293) and (293’) usable with any of the aforementioned examples (such as, but not limited, the example of FIGs. 26-27D). Both260493.000069versions incorporate a sloped distal edge (293.1) and (293.1’) that allows for easier alignment and insertion into the neck of the cartridge (202A) or (202B). Whereas the spigot plug component (293’) of FIGs. 29A-29D is solid in a region of its distalmost rib (293.2’) and can have a conical shape at its distal end, the spigot plug component (293) of FIGs. 28A-28D comprises a recess (293.2) formed into the distal edge (293.1) in such a way that it overlaps with the distalmost rib (293.3). The recess (293.2) allows for some compression in the distalmost rib (293.3) on the spigot plug component (293) both during assembly and in use when it is being inserted through the cartridge neck and into the piston component (294A) or (294B).

[0184] FIGs. 30A-30D depict various views of an exemplary plunger stopper (328) usable with any of the aforementioned examples (such as, but not limited, the example of FIGs. 26-27D). The plunger stopper (328) has a threaded interior and is larger than conventional plunger stoppers. By way of example, the plunger stopper (328) can have an outer diameter D of approximately 7.25 millimeters and a height H of approximately 6.5 millimeters.

[0185] FIG. 31 is a flowchart for an example method (3100) for using a syringe assembly. Method (3100) includes connecting (3105) a needle hub to a distal end of a housing. Method (3100) includes inserting (3110) a first pharmaceutical componentmixing delivery assembly into a proximal end of the housing. Method (3100) includes inserting (3115) a second pharmaceutical component-mixing delivery assembly into the proximal end of the housing. Method (3100) includes securing (3120) the first and second pharmaceutical component-mixing delivery assemblies within the housing. Method (3100) includes moving (3125) the needle hub from a first position with respect to the housing to a second position with respect to the housing, such that a first and second transfer needles of the needle hub move proximally toward the first and second pharmaceutical component-mixing delivery assemblies. Method (3100) includes piercing (3130), in response to proximal movement of the first and second transfer needles, a first seal of the first pharmaceutical component-mixing delivery assembly with the first transfer needle and a second seal of the second pharmaceutical component-mixing delivery assembly with the second transfer needle.260493.000069

[0186] Aspects of the present disclosure can be provided by any of the following clauses.Clause 1. A syringe assembly comprising: a housing; and a needle hub engageable with the housing and movable from a first position with respect to the housing to a second position with respect to the housing, the needle hub comprising: a needle connector positioned such that the needle connector faces away from the housing when the needle hub is engaged with the housing; a first transfer needle oriented such that the first transfer needle extends away from the needle connector, the first transfer needle configured to pierce a seal of a first pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position; and a second transfer needle positioned such that the second transfer needle extends away from the needle connector, the second transfer needle configured to pierce a seal of a second pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position.Clause 2. The syringe assembly of Clause 1, wherein the second position is spaced, along a longitudinal axis of the housing, from the first position.Clause 3. The syringe assembly of Clause 1, wherein the needle hub is slidable relative to the housing to move the needle hub from the first position to the second position.Clause 4. The syringe assembly of Clause 1, wherein the first transfer needle and the second transfer needle are connected to each other at a convergence conduit that is disposed in the needle hub.Clause 5. The syringe assembly of Clause 4, wherein the convergence conduit connects the first transfer needle and the second transfer needle to the needle connector. Clause 6. The syringe assembly of Clause 4, wherein the first transfer needle and the second transfer needle each comprise a bend oriented such that a portion of the first transfer needle and a portion of the second transfer needle extend approximately parallel to the convergence conduit.Clause 7. The syringe assembly of Clause 1, wherein the needle connector comprises a luer lock connection.260493.000069Clause 8. The syringe assembly of Clause 1, wherein the needle hub is moveable from the first position to the second position responsive to attaching a delivery needle thereto.Clause 9. The syringe assembly of Clause 1, wherein the needle hub is moveable from the first position to the second position responsive to a user advancing the needle hub proximally so as to prime the syringe assembly for medicament delivery.Clause 10. The syringe assembly of Clause 1, further comprising a plunger comprising a first plunger rod configured to be depressed into the first pharmaceutical component-mixing delivery assembly and a second plunger rod configured to be depressed into the second pharmaceutical component-mixing delivery assembly.Clause 11. The syringe assembly of Clause 1, further comprising a first plunger stopper configured to be inserted into the first pharmaceutical component-mixing delivery assembly and a second plunger stopper configured to be inserted into the second pharmaceutical component-mixing delivery assembly.Clause 12. The syringe assembly of Clause 11, wherein at least the first plunger stopper or the second plunger stopper comprises a diameter of approximately 7.25 millimeters and a height of approximately 6.5 millimeters.Clause 13. The syringe assembly of Clause 1, further comprising: a first piston component; a second piston component; a first spigot plug component housed in the first piston component; and a second spigot plug component housed in the second piston component.Clause 14. The syringe assembly of Clause 13, wherein at least the first spigot plug component or the second spigot plug component comprises a sloped distal edge that defines a solid conical shape.Clause 15. The syringe assembly of Clause 13, wherein at least the first spigot plug component or the second spigot plug component comprises a sloped distal edge, a distalmost rib, and a recess formed through the distal edge so as to overlap with the distalmost rib.Clause 16. The syringe assembly of Clause 1, wherein the first pharmaceutical component-mixing delivery assembly comprises a first cartridge and a second cartridge, the first cartridge and the second cartridge being dimensioned so that they are movable260493.000069relative to one another such that the first cartridge is slidable within the second cartridge.Clause 17. The syringe assembly of Clause 16, wherein the first cartridge comprises a first liquid pharmaceutical component, and wherein the second cartridge comprises a first solid pharmaceutical component.Clause 18. The syringe assembly of Clause 17, wherein the second pharmaceutical component-mixing delivery assembly comprises a third cartridge and a fourth cartridge, the third cartridge and the fourth cartridge being dimensioned so that they are movable relative to one another such that the third cartridge is slidable within the fourth cartridge.Clause 19. The syringe assembly of Clause 18, wherein the third cartridge comprises a second liquid pharmaceutical component, and wherein the fourth cartridge comprises a second solid pharmaceutical component.Clause 20. The syringe assembly of Clause 19, wherein the first liquid pharmaceutical component and the second liquid pharmaceutical component comprise an identical composition.Clause 21. The syringe assembly of Clause 19, wherein the first liquid pharmaceutical component and the second liquid pharmaceutical component comprise different compositions.Clause 22. The syringe assembly of Clause 19, wherein the first solid pharmaceutical component and the second solid pharmaceutical component comprise an identical composition.Clause 23. The syringe assembly of Clause 19, wherein the first solid pharmaceutical component and the second solid pharmaceutical component comprise different compositions.Clause 24. A kit comprising the needle hub, the housing, the first pharmaceutical component-mixing delivery assembly, and the second pharmaceutical componentmixing delivery assembly of any one of Clauses 16 to 23.Clause 25. The kit of Clause 24, wherein the first pharmaceutical componentmixing delivery assembly and the second pharmaceutical component-mixing delivery assembly are fluidically isolated from one another in the first position of the needle hub.260493.000069Clause 26. A method comprising: connecting a needle hub to a distal end of a housing; inserting a first pharmaceutical component-mixing delivery assembly into a proximal end of the housing; inserting a second pharmaceutical component-mixing delivery assembly into the proximal end of the housing; securing the first and second pharmaceutical component-mixing deliveries assembly within the housing; moving the needle hub from a first position with respect to the housing to a second position with respect to the housing, such that first and second transfer needles of the needle hub moves proximally toward the first and second pharmaceutical component-mixing delivery assemblies; and piercing, in response to proximal movement of the first and second transfer needles, a first seal of the first pharmaceutical component-mixing delivery assembly with the first transfer needle and a second seal of the second pharmaceutical component-mixing delivery assembly with the second transfer needle. Clause 27. The method of Clause 26, further comprising attaching a delivery needle to a needle connector of the needle hub.Clause 28. The method of Clause 27, wherein the needle connector comprises a luer lock connection.Clause 29. The method of Clause 27, wherein the needle hub is moveable from the first position to the second position responsive to attaching the delivery needle to the needle connector.Clause 30. The method of Clause 26, wherein the needle hub is moveable from the first position to the second position responsive to a user advancing the needle hub proximally so as to prime the first pharmaceutical component-mixing delivery assembly and the second pharmaceutical component-mixing delivery assembly for medicament delivery.Clause 31. The method of Clause 26, further comprising: advancing a plunger distally to deliver (i) a first reconstituted pharmaceutical component through the first transfer needle and through a convergence conduit and (ii) a second reconstituted pharmaceutical component through the second transfer needle and through the convergence conduit.Clause 32. The method of Claim 31, wherein a total volume of reconstituted pharmaceutical component delivered through the convergence conduit is at least 6 mb.260493.000069Clause 33. A system comprising: a first pharmaceutical component-mixing delivery assembly containing a first pharmaceutical component; a second pharmaceutical component-mixing delivery assembly containing a second pharmaceutical component; and a syringe assembly comprising: a housing, the first and second pharmaceutical component-mixing delivery assemblies being disposed within the housing; a fluidic path; and an outlet through which the first pharmaceutical component and the second pharmaceutical component are configured to exit the syringe assembly, the outlet being connected to the fluidic path such that the first component and the second component are configured to converge prior to exiting the syringe assembly.Clause 34. The system of Clause 33, further comprising a needle hub engageable with the housing and movable from a first position with respect to the housing to a second position with respect to the housing, the needle hub comprising: the outlet, the outlet being positioned such that the outlet faces away from the housing when the needle hub is engaged with the housing; a first transfer needle forming a first portion of the fluidic path and oriented such that the first transfer needle extends away from the outlet, the first transfer needle configured to pierce a seal of the first pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position; a second transfer needle forming a second portion of the fluidic path and positioned such that the second transfer needle extends away from the outlet, the second transfer needle configured to pierce a seal of the second pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position; and a convergence conduit forming a third portion of the fluidic path, the convergence conduit connecting the first transfer needle and the second transfer needle to the outlet.Clause 35. The system of Clause 33, wherein the outlet comprises a needle connector.

[0187] It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure which will be limited only by the appended claims.

[0188] Ranges may be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, also specifically260493.000069contemplated and considered disclosed is the range from the one particular value and / or to the other particular value unless the context specifically indicates otherwise. Similarly, when values are expressed as approximations, by use of the antecedent “about” or “approximately,” it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise. The term “about” or “approximately” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

[0189] “Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.

[0190] The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. Thus, as a non-limiting example, a reference to “A and / or B,” when used in conjunction with open-ended language such as “comprising” can refer, in some embodiments, to A without B (optionally including elements other than B); in another embodiments, to B without A (optionally including elements other than A); in yet another embodiments, to both A and B (optionally including other elements); etc.

[0191] The following reference numbers are used in this detailed disclosure.Ref: Component260493.0000691 Pharmaceutical 25 BallComponent-Mixing 26 T-Valve Component Delivery Assembly 27 First Hollow Piston 2 First Cartridge 28 Second Hollow Piston 3 Second Cartridge 29 Side Wall4 Body 30 Side Wall5 Outlet End 31 Circumferential Recess 6 Plunger 32 Stopper Component 7 First Pharmaceutical 33 Internal Conduit Component 34 Branched Conduit 8 Body 35 Second Stopper 9 Inlet End Component10 Outlet End 36 Internal Conduit 11 Second Pharmaceutical 37 Branched Conduit Component 38 Annular Valve 12 Non-Invasive Valve Component Component 39 Round Stopper 13 Ball Valve Component14 Hollow Piston 40 First Hollow Piston 15 First End 41 Second Hollow Piston 16 Second End 42 Side Wall16b Central Spigot 43 Side Wall17 Inlet End 44 Circumferential Recess 18 Side Wall 45 First Stopper19 Inner Surface Component20 Circumferential Recess 46 Circumferential 21 Circumferential Shoulder Shoulder 47 Orifices 22 Apertures 48 Orifice24 Orifice260493.00006949 Second Stopper 78 Outlet End Component 79 Outlet End 50 Outlet End 80 Inlet End51 Plunger End 82 Side Wall52 Surface 83 Piston53 Stopper 84 External Circumferential 54 Orifice Ribs55 Inner Surface 85 Side Wall56 Surface 86 Inner Wall57 Plug Component 87 Terminal Rib58 First Seal 88 End59 Needle 89 Mixing Chamber 60 Second Seal 92 Lip61 Septum 93 Spigot Plug Component 62 Guide Channel 94 Piston Component 63 Spigot Plug Component 95 Circumferential Ribs 64 Piston Component 96 T-Shaped Conduit 65 T-Shaped Component 97 Outer Casing66 First End 98 Frangible Seal67 Second End 99 Channels69 Side Wall 100 Needle Hub70 Lip 102 Transfer Needle 71 Conduit 104 Snapper72 Hollow Plug Component 105 Centering Guide 73 Piston Component 106 Needle Connector 74 Lip 108 Housing75 Stopper 109 Longitudinal Grooves 76 T-Shaped Conduit 110 Visualization Windows77 Inlet End260493.000069112 First Snapper 160 Inside Surface Engagement Location 161 Proximal End Surface 114 Second Snapper 161A Notch Engagement Location 162 Textured Grip115 Cartridge Cap 170 Seal116 Pierceable Seal 172 Perforation118 Stop 174 Proximal Edge120 Delivery Needle 176 Cutouts122 Safety Cap 201A First Pharmaceutical 124 End Cap Component-Mixing 126 Plunger Aperture Delivery Assembly 128 Plunger Stopper 201B Second Pharmaceutical 130 Lugs Component-Mixing 130A First Lug Delivery Assembly I30B Second Lug 202A First Cartridge132 Angled Groove 202B Third Cartridge 134 Starting Slot 203A Second Cartridge 136 First Wall Snap 203B Fourth Cartridge 138 Ending Slot 206 Plunger140 Second Wall Snap 206A First Plunger Rod 142 Threads 206B Second Plunger Rod 144 Gas Vent 207A First Pharmaceutical 146 Circumferential Seal Component150 Track 207B Third Pharmaceutical 152 Vertical Track Component152A First Vertical Track 211A Second Pharmaceutical 152B Second Vertical Track Component154 Horizontal Track 211B Fourth Pharmaceutical 156 Loading Chamfer Component293 Spigot Plug Component260493.000069293.1 Sloped Distal Edge 300 Needle Hub293.2 Distalmost Rib 302 A First Transfer Needle 293.3 Recess 302B Second Transfer Needle 293A First Spigot Plug 302C Convergence Conduit Component 303A First Bend 293B Second Spigot Plug 303B Second Bend Component 306 Needle Connector 293’ Alternative Spigot Plug 308 Housing Component 316A First Seal 293.1’ Sloped Distal Edge 316B Second Seal 293.2’ Distalmost Rib 328 Plunger Stopper 294A First Piston Component 328A First Plunger Stopper 294B Second Piston 328B Second Plunger Stopper Component 201A First Pharmaceutical 295A First Circumferential Component-Mixing Ribs Delivery Assembly 295B Second Circumferential 201B Second Pharmaceutical Ribs Component-Mixing 296A First T-Shaped Conduit Delivery Assembly296B Second T-ShapedConduit

Claims

260493.000069CLAIMS1. A syringe assembly comprising:a housing; anda needle hub engageable with the housing and movable from a first position with respect to the housing to a second position with respect to the housing, the needle hub comprising:a needle connector positioned such that the needle connector faces away from the housing when the needle hub is engaged with the housing;a first transfer needle oriented such that the first transfer needle extends away from the needle connector, the first transfer needle configured to pierce a seal of a first pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position; anda second transfer needle positioned such that the second transfer needle extends away from the needle connector, the second transfer needle configured to pierce a seal of a second pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position.

2. The syringe assembly of Claim 1, wherein the second position is spaced, along a longitudinal axis of the housing, from the first position.

3. The syringe assembly of Claim 1, wherein the needle hub is slidable relative to the housing to move the needle hub from the first position to the second position.

4. The syringe assembly of Claim 1, wherein the first transfer needle and the second transfer needle are connected to each other at a convergence conduit that is disposed in the needle hub.

5. The syringe assembly of Claim 4, wherein the convergence conduit connects the first transfer needle and the second transfer needle to the needle connector.260493.0000696. The syringe assembly of Claim 4, wherein the first transfer needle and the second transfer needle each comprise a bend oriented such that a portion of the first transfer needle and a portion of the second transfer needle extend approximately parallel to the convergence conduit.

7. The syringe assembly of Claim 1, wherein the needle connector comprises a luer lock connection.

8. The syringe assembly of Claim 1, wherein the needle hub is moveable from the first position to the second position responsive to attaching a delivery needle thereto.

9. The syringe assembly of Claim 1, wherein the needle hub is moveable from the first position to the second position responsive to a user advancing the needle hub proximally so as to prime the syringe assembly for medicament delivery.

10. The syringe assembly of Claim 1, further comprising a plunger comprising a first plunger rod configured to be depressed into the first pharmaceutical componentmixing delivery assembly and a second plunger rod configured to be depressed into the second pharmaceutical component-mixing delivery assembly.

11. The syringe assembly of Claim 1, further comprising a first plunger stopper configured to be inserted into the first pharmaceutical component-mixing delivery assembly and a second plunger stopper configured to be inserted into the second pharmaceutical component-mixing delivery assembly.

12. The syringe assembly of Claim 11, wherein at least the first plunger stopper or the second plunger stopper comprises a diameter of approximately 7.25 millimeters and a height of approximately 6.5 millimeters.

13. The syringe assembly of Claim 1, further comprising:260493.000069a first piston component;a second piston component;a first spigot plug component housed in the first piston component; and a second spigot plug component housed in the second piston component.

14. The syringe assembly of Claim 13, wherein at least the first spigot plug component or the second spigot plug component comprises a sloped distal edge that defines a solid conical shape.

15. The syringe assembly of Claim 13, wherein at least the first spigot plug component or the second spigot plug component comprises a sloped distal edge, a distalmost rib, and a recess formed through the distal edge so as to overlap with the distalmost rib.

16. The syringe assembly of Claim 1, wherein the first pharmaceutical componentmixing delivery assembly comprises a first cartridge and a second cartridge, the first cartridge and the second cartridge being dimensioned so that they are movable relative to one another such that the first cartridge is slidable within the second cartridge.

17. The syringe assembly of Claim 16, wherein the first cartridge comprises a first liquid pharmaceutical component, and wherein the second cartridge comprises a first solid pharmaceutical component.

18. The syringe assembly of claim 17, wherein the second pharmaceutical component-mixing delivery assembly comprises a third cartridge and a fourth cartridge, the third cartridge and the fourth cartridge being dimensioned so that they are movable relative to one another such that the third cartridge is slidable within the fourth cartridge.260493.00006919. The syringe assembly of Claim 18, wherein the third cartridge comprises a second liquid pharmaceutical component, and wherein the fourth cartridge comprises a second solid pharmaceutical component.

20. The syringe assembly of Claim 19, wherein the first liquid pharmaceutical component and the second liquid pharmaceutical component comprise an identical composition.

21. The syringe assembly of Claim 19, wherein the first liquid pharmaceutical component and the second liquid pharmaceutical component comprise different compositions.

22. The syringe assembly of Claim 19, wherein the first solid pharmaceutical component and the second solid pharmaceutical component comprise an identical composition.

23. The syringe assembly of Claim 19, wherein the first solid pharmaceutical component and the second solid pharmaceutical component comprise different compositions.

24. A kit comprising the needle hub, the housing, the first pharmaceutical component-mixing delivery assembly, and the second pharmaceutical componentmixing delivery assembly of any one of Claims 16 to 23.

25. The kit of claim 24, wherein the first pharmaceutical component-mixing delivery assembly and the second pharmaceutical component-mixing delivery assembly are fluidically isolated from one another in the first position of the needle hub.

26. A method comprising:connecting a needle hub to a distal end of a housing;260493.000069inserting a first pharmaceutical component-mixing delivery assembly into a proximal end of the housing;inserting a second pharmaceutical component-mixing delivery assembly into the proximal end of the housing;securing the first and second pharmaceutical component-mixing deliveries assembly within the housing;moving the needle hub from a first position with respect to the housing to a second position with respect to the housing, such that first and second transfer needles of the needle hub moves proximally toward the first and second pharmaceutical component-mixing delivery assemblies; andpiercing, in response to proximal movement of the first and second transfer needles, a first seal of the first pharmaceutical component-mixing delivery assembly with the first transfer needle and a second seal of the second pharmaceutical component-mixing delivery assembly with the second transfer needle.

27. The method of Claim 26, further comprising attaching a delivery needle to a needle connector of the needle hub.

28. The method of Claim 27, wherein the needle connector comprises a luer lock connection.

29. The method of Claim 27, wherein the needle hub is moveable from the first position to the second position responsive to attaching the delivery needle to the needle connector.

30. The method of Claim 26, wherein the needle hub is moveable from the first position to the second position responsive to a user advancing the needle hub proximally so as to prime the first pharmaceutical component-mixing delivery assembly and the second pharmaceutical component-mixing delivery assembly for medicament delivery.260493.00006931. The method of Claim 26, further comprising:advancing a plunger distally to deliver (i) a first reconstituted pharmaceutical component through the first transfer needle and through a convergence conduit and (ii) a second reconstituted pharmaceutical component through the second transfer needle and through the convergence conduit.

32. The method of Claim 31, wherein a total volume of reconstituted pharmaceutical component delivered through the convergence conduit is at least 6 mL.

33. A system comprising:a first pharmaceutical component-mixing delivery assembly containing a first pharmaceutical component;a second pharmaceutical component-mixing delivery assembly containing a second pharmaceutical component; anda syringe assembly comprising:a housing, the first and second pharmaceutical component-mixing delivery assemblies being disposed within the housing;a fluidic path; andan outlet through which the first pharmaceutical component and the second pharmaceutical component are configured to exit the syringe assembly, the outlet being connected to the fluidic path such that the first component and the second component are configured to converge prior to exiting the syringe assembly.

34. The system of Claim 33, further comprising a needle hub engageable with the housing and movable from a first position with respect to the housing to a second position with respect to the housing, the needle hub comprising:the outlet, the outlet being positioned such that the outlet faces away from the housing when the needle hub is engaged with the housing;a first transfer needle forming a first portion of the fluidic path and oriented such that the first transfer needle extends away from the outlet, the first transfer needle260493.000069configured to pierce a seal of the first pharmaceutical component-mixing delivery assembly when the needle hub is moved from the first position to the second position;a second transfer needle forming a second portion of the fluidic path and positioned such that the second transfer needle extends away from the outlet, the second transfer needle configured to pierce a seal of the second pharmaceutical componentmixing delivery assembly when the needle hub is moved from the first position to the second position; anda convergence conduit forming a third portion of the fluidic path, the convergence conduit connecting the first transfer needle and the second transfer needle to the outlet.

35. The system of Claim 33, wherein the outlet comprises a needle connector.